Condition in which the plasma levels of homocysteine and related metabolites are elevated (
| Excerpt | Reference |
|---|
| "Hyperhomocysteinemia is now regarded as an established risk factor for coronary artery disease and is present frequently in the general population." | ( Bissé, E; Dierkes, J; Luley, C; Mayer, H; Nauck, M; Orth, M; Wieland, H, 1998) |
| "Hyperhomocysteinemia is now recognized as a common risk factor for thrombotic vascular events such as stroke, myocardial infarction, and venous thrombosis." | ( Lentz, SR, 1998) |
| "Hyperhomocysteinemia is independently associated with coronary artery disease in Arab men." | ( Asmi, M; Busjahn, A; Joubran, R; Jouma, M; Luft, FC; Vergopoulos, A, 1998) |
| "Hyperhomocysteinemia is a risk factor for arterial diseases, and the deterioration of the arterial elastic structures is one of the possible mechanisms underlying this epidemiological association." | ( Augier, T; Bescond, A; Chareyre, C; Charpiot, P; Fraterno, M; Garçon, D; Rolland, PH, 1998) |
| "Hyperhomocysteinemia is a major and independent risk factor for vascular disease." | ( Chambers, JC; Jean-Marie, J; Kooner, JS; McGregor, A; Obeid, OA, 1999) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerotic complications in patients with end-stage renal disease, although the mechanisms remain unclear." | ( Arheart, K; Dennis, VW; Gupta, A; Jacobsen, DW; Moustapha, A; Robinson, K; Schreiber, MJ, 1999) |
| "Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD." | ( Arheart, K; Dennis, VW; Gupta, A; Jacobsen, DW; Moustapha, A; Robinson, K; Schreiber, MJ, 1999) |
| "Many cases (47%) of hyperhomocysteinemia are not associated with micronutrient deficiencies, impaired renal function, and/or currently known genetic mutations." | ( Bignell, MK; Bullemer, FE; Graham, KJ; Hanson, NQ; Rasmussen, R; Schwichtenberg, K; Tsai, MY; Vessey, J; Welge, BG; Yang, F, 1999) |
| "Moderate hyperhomocysteinemia is a risk factor for arterial vascular disease and venous thrombosis in adults." | ( Blom, HJ; den Heijer, M; Smeitink, JA; te Poele Pothoff, MT; van Beynum, IM, 1999) |
| "Mild hyperhomocysteinemia is an independent risk factor for increased carotid artery wall thickness and plaque formation in a general population." | ( Beilby, JP; Hung, J; McQuillan, BM; Nidorf, M; Thompson, PL, 1999) |
| "Mild hyperhomocysteinemia is estimated to occur in 5-10% of the general population." | ( Andreotti, F; Burzotta, F; Manzoli, A; Maseri, A; Mazza, A; Robinson, K, 1999) |
| "Moderate hyperhomocysteinemia is an atherogenic risk factor and plays an important role in geriatrics." | ( Bodis, M; Geisel, J; Herrmann, W; Quast, S; Schultze, H; Ullrich, M, 1999) |
| "Severe hyperhomocysteinemia is due to rare genetic defects resulting in deficiencies in cystathionine beta synthase, methylenetetrahydrofolate reductase, or in enzymes involved in methyl-B12 synthesis and homocysteine methylation." | ( Selhub, J, 1999) |
| "Hyperhomocysteinemia is a condition caused by both genetic and nongenetic factors." | ( Hong, SB; Yoo, JH, 1999) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases." | ( Blom, H; de Boer, AW; Giesen, AM; Monnens, LA; Schröder, CH, 1999) |
| "Hyperhomocysteinemia is an independent risk factor for coronary, peripheral, and cerebrovascular disease." | ( Faiman, C; Green, R; Hussein, WI; Jacobsen, DW, 1999) |
| "Our data show that hyperhomocysteinemia is frequently found in arterial and venous thrombosis." | ( Cacoub, P; Foglietti, MJ; Godeau, P; Hamidou, S; Hausfater, P; Jacob, N; Piette, JC; Tazi, Z, 2000) |
| "We concluded that hyperhomocysteinemia is very frequent in RTP, but homocysteine levels are not different in patients treated with cyclosporine or tacrolimus." | ( Andrés, A; Carillo, JL; Díaz-Rubio, P; Estenoz, J; Fernández-Miranda, C; Gómez, P; Morales, JM, 2000) |
| "Among the causes of hyperhomocysteinemia is depletion of folate, vitamin B12, or vitamin B6." | ( Bagley, PJ; Choi, SW; Kim, YI; Mason, JB; Russell, RM; Seitz, HK; Selhub, J; Stickel, F, 2000) |
| "The prevalence of hyperhomocysteinemia is increased in critically ill patients compared to age- and gender-matched healthy individuals." | ( Bieglmayer, C; Buchmayer, H; Födinger, M; Heinz, G; Hörl, WH; Schindler, K; Sunder-Plassmann, G; Wilfing, A; Wölfl, G; Zauner, C, 2000) |
| "Hyperhomocysteinemia is a risk factor for central retinal vein occlusion and may suggest a poor prognosis in patients with central retinal vein occlusion." | ( Vine, AK, 2000) |
| "Mild hyperhomocysteinemia is common among maintenance hemodialysis (HD) patients and renal transplant recipients (RTR) and may contribute to the excess incidence of arteriosclerotic outcomes experienced by both patient groups." | ( Beaulieu, AJ; Bostom, AG; Dworkin, L; Gohh, RY; Jacques, PF; Selhub, J; Shemin, D, 2000) |
| "Causes of hyperhomocysteinemia are hereditary heterozygous or, in very rare cases, homozygous defects, and quite frequently a lack of the coenzymes B6 and B12 and the cosubstrate folate." | ( Kircher, T; Sinzinger, H, 2000) |
| "Hyperhomocysteinemia is a risk factor for stroke, myocardial infarction, and venous thrombosis." | ( Dayal, S; Erger, RA; Faraci, FM; Heistad, DD; Lentz, SR; Maeda, N; Malinow, MR, 2000) |
| "Hyperhomocysteinemia is frequently associated with congenital defects of the heart and neural tube and is a suspected pathogenic factor in atherosclerosis and neoplasia." | ( Dalton, M; Gadson, P; Limpach, A; Miles, R, 2000) |
| "Hyperhomocysteinemia is a risk factor for arteriosclerosis and venous thrombosis, and given the propensity of patients with sickle cell disease to develop ischemic complications, we hypothesized that they might have elevated plasma homocysteine concentrations." | ( Cornwell, PE; Lowenthal, EA; Mayo, MS; Thornley-Brown, D, 2000) |
| "Hyperhomocysteinemia is an independent risk factor for coronary heart disease." | ( Gao, W; Jiang, N; Zhu, G, 1998) |
| "Hyperhomocysteinemia is associated with increased risk of atherosclerotic and thrombotic vascular disease." | ( Heistad, DD; Lentz, SR; Malinow, MR; Piegors, DJ, 2001) |
| "Hyperhomocysteinemia is a risk factor for central retinal vein occlusion." | ( Vine, AK, 2000) |
| "Hyperhomocysteinemia is a risk factor for arterial and venous thrombosis." | ( Alfie, J; Galarza, C; Kordich, L; Murúa, A; Quintana, I, 2001) |
| "In conclusion, mild hyperhomocysteinemia is common in Greek IBD patients and may account for the increased thrombotic risk of these patients." | ( Dilaveraki, E; Emmanouel, D; Ganotakis, E; Gravanis, A; Kouroumalis, EA; Koutroubakis, IE; Mouzas, IA; Vardas, E; Vlachonikolis, IG; Vrentzos, G, 2000) |
| "Hyperhomocysteinemia is associated with a significant decrease of the smooth muscle cell/extracellular matrix ratio of the media of muscular femoral arteries without significant changes in medial thickness." | ( Bogels, M; Niessen, HW; Rauwerda, JA; Stehouwer, CD; van Hinsbergh, VW; Vermeulen, EG, 2001) |
| "Hyperhomocysteinemia is related to poor recall and this association was partially independent of folate status." | ( Jacques, PF; Morris, MS; Rosenberg, IH; Selhub, J, 2001) |
| "Hyperhomocysteinemia is a cardiovascular disease (CVD) risk factor." | ( Dijck-Brouwer, DA; Fokkema, MR; Muskiet, FA; van Doormaal, JJ; Weijer, JM, 2001) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Thus, hyperhomocysteinemia is a prominent risk for DVT in Taiwan." | ( Chang, CJ; Chiang, CW; Hsu, LA; Hsu, TS; Ko, YL; Kuo, CT; Lee, YS; Sun, CF, 2001) |
| "Hyperhomocysteinemia is associated with increased risk for cardiovascular events, but it is not certain whether it is a mediator of vascular dysfunction or a marker for another risk factor." | ( Arning, E; Bottiglieri, T; Dayal, S; Faraci, FM; Heistad, DD; Lentz, SR; Maeda, N; Malinow, MR; Sigmund, CD, 2001) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerosis and atherothrombosis." | ( Desai, A; Lankford, HA; Warren, JS, 2001) |
| "Hyperhomocysteinemia is a strong risk factor for atherosclerotic vascular disease, and elevated serum homocysteine is correlated with vitamin B deficiency." | ( Artner-Dworzak, E; Fuchs, D; Leblhuber, F; Reibnegger, G; Vrecko, K; Walli, J; Widner, B, 2000) |
| "Hyperhomocysteinemia is known to be associated with an increased risk of myocardial infarction, stroke, peripheral arterial disease, and venous thrombosis." | ( Choi, JR; Kim, HK; Kim, JH; Shin, JS; Song, JW; Song, KS, 2001) |
| "Hyperhomocysteinemia is significantly more common in patients with IBD compared with healthy controls, and is associated with lower (but not necessarily deficient) vitamin B12 levels." | ( Bamforth, F; Dias, VC; Fedorak, RN; Romagnuolo, J; Teltscher, M, 2001) |
| "Hyperhomocysteinemia is caused by both nutritional (e." | ( Barbaux, S; Evans, A; Gaughan, DJ; Kluijtmans, LA; McMaster, D; Whitehead, AS; Yarnell, JW; Young, IS, 2001) |
| "To determine if hyperhomocysteinemia is a risk factor for the development of diabetic sensorimotor peripheral neuropathy (DSPN) and diabetic autonomic neuropathy (DAN)." | ( Cohen, JA; Estascio, R; Jeffers, BW; Schrier, RW; Stabler, S, 2001) |
| "Hyperhomocysteinemia is also associated with a higher risk of venous thrombosis to which other coagulation disorders, such as factor V Leiden, could contribute." | ( Barbado Hernández, FJ; Gómez Cerezo, JF; Ríos Blanco, JJ; Suárez García, I; Vázquez Rodríguez, JJ, 2001) |
| "Hyperhomocysteinemia is a well established risk factor for atherothrombotic disease, and the request for homocysteine determinations and the number of laboratories that need to perform this assay to assess individual risk profile is increasing." | ( Abbate, R; Brunelli, T; Fedi, S; Giusti, B; Marcucci, R; Pepe, G; Prisco, D, 2001) |
| "Hyperhomocysteinemia is an independent risk factor for atherothrombosis." | ( Austin, RC; Bentzon, J; Danielsen, CC; Falk, E; Møller, J; Ravn, HB; Zhou, J, 2001) |
| "Hyperhomocysteinemia is the result of a disturbed methionine metabolism." | ( Herrmann, W, 2001) |
| "Hyperhomocysteinemia is considered as a risk factor for cardiovascular diseases." | ( Artner-Dworzak, E; Fuchs, D; Jaeger, M; Leblhuber, F; Widner, B; Wirleitner, B, 2001) |
| "Hyperhomocysteinemia is an independent risk factor for coronary disease and elevated plasma homocysteine levels have been documented in heart transplant recipients." | ( Alimollah, A; Gao, SZ; Giannetti, N; Herity, NA; Hunt, SA; Schroeder, JS; Valantine, HA; Yeung, AC, 2001) |
| "Mild hyperhomocysteinemia is a consistent finding among heart transplant recipients." | ( Alimollah, A; Gao, SZ; Giannetti, N; Herity, NA; Hunt, SA; Schroeder, JS; Valantine, HA; Yeung, AC, 2001) |
| "Hyperhomocysteinemia is a putative risk factor for cardiovascular disease, which also impairs endothelium-dependent vasodilatation." | ( Balint, RF; Cooke, JP; Her, JH; Kimoto, M; Stühlinger, MC; Tsao, PS, 2001) |
| "Hyperhomocysteinemia is an independent risk factor of CHD." | ( Chen, Z; Tang, J; Xu, H, 1999) |
| "Mild hyperhomocysteinemia is an independent risk factor for cardiovascular disease and may result from a deficiency of folate, vitamin B-6 or vitamin B-12." | ( Chang, SJ; Chou, HF; Huang, HB; Huang, PC; Hung, CJ; Li, YH; Lin, BF; Lu, SC, 2002) |
| "Hyperhomocysteinemia is considered a risk factor for cardiovascular disease and is prevalent in the elderly." | ( Barrera, G; Bunout, D; de la Maza, P; Gattás, V; Hirsch, S; Petermann, M, 2002) |
| "Experimentally, hyperhomocysteinemia is not in itself atherogenic in normal animals with relatively low plasma cholesterol levels." | ( Falk, E; Møller, J; Zhou, J, 2001) |
| "Hyperhomocysteinemia is a common finding in APS patients, and may contribute to severity of thrombotic tendency observed in this syndrome." | ( Avivi, I; Brenner, B; Hoffman, R; Lanir, N, 2002) |
| "Hyperhomocysteinemia is an independent risk factor for vascular disease, frequently observed in patients with severe renal impairment." | ( Corrocher, R; Faccini, G; Friso, S; Girelli, D; Olivieri, O; Pignatti, PF; Pizzolo, F; Stranieri, C; Trabetti, E, 2001) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disease." | ( Jackson, SH; Mangoni, AA, 2002) |
| "Hyperhomocysteinemia is a well-established risk factor for cardiovascular disease." | ( Asnani, S; Desouza, C; Fonseca, V; Homan, J; McNamara, DB; Murthy, SN, 2002) |
| "Mild to moderate hyperhomocysteinemia is very common among patients undergoing haemodialysis." | ( Costimba, I; Delaportas, N; Georgalidis, C; Kaliolia, I; Karaliotas, G; Katsarou, A; Klonou, E; Koulouridis, E; Krokida, A; Lachanas, A; Panagiotaki, E; Tzilianos, M, 2001) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis and venous thrombosis, probably exerting its effects through endothelial function." | ( Forsblad, J; Gottsäter, A; Lindgärde, F; Mattiasson, I, 2002) |
| "Mild hyperhomocysteinemia is associated with homozygosity for the thermolabile variant of 5,10-methylenetetrahydrofolate reductase (MTHFR) and could increase the risk of venous thromboembolic disease (VTD)." | ( Adamek, L; Domagala, TB; Nizankowska, E; Sanak, M; Szczeklik, A, 2002) |
| "Hyperhomocysteinemia is a well-known independent risk factor for cardiovascular disease and is a prevalent abnormality in chronic renal failure." | ( Cheong, HI; Choi, Y; Ha, IS; Hahn, H; Kang, HG; Lee, BS; Lee, JH, 2002) |
| "Hyperhomocysteinemia is an independent risk factor for the development of atherosclerosis in adult patients on dialysis or after kidney transplantation." | ( Becker-Cohen, R; Drukker, A; Feinstein, S; Frishberg, Y; Gavendo, S; Raveh, D; Sela, BA, 2002) |
| "Hyperhomocysteinemia is an independent risk factor for CAD." | ( Aengevaeren, WR; Blom, HJ; Boers, GH; Verheugt, FW; Willems, FF, 2002) |
| "Hyperhomocysteinemia is an independent cardiovascular risk factor." | ( Baydas, G; Canatan, H; Canpolat, S; Cikim, G; Gursu, MF; Kelestimur, H; Yasar, A, 2002) |
| "Hyperhomocysteinemia is considered to be a risk factor for vascular diseases including ischemic stroke." | ( Kaji, M; Kondo, I; Metoki, N; Sato, Y; Satoh, K; Yoshida, H, 2002) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular events." | ( Doulgerakis, C; Karakasis, P; Kountouris, S; Kourvelou, C; Papagalanis, N; Rammos, G; Ziakka, S, 2001) |
| "While hyperhomocysteinemia is associated with an increased risk of atherosclerosis and the related cardiovascular diseases, the effect of hyperhomocysteinemia on the kidney has not been clearly demonstrated." | ( Hirosawa, K; Hishida, A; Ikegaya, N; Katoh, S; Kimura, M; Kumagai, H, 2002) |
| "Hyperhomocysteinemia is associated with abnormal endothelium-dependent vasodilation in peripheral human arteries." | ( Alpert, NM; Cooke, JP; Creager, MA; Fischman, AJ; Forgione, MA; Gewirtz, H; Loscalzo, J; Stuehlinger, M; Tawakol, A, 2002) |
| "Mild hyperhomocysteinemia is not associated with endothelial dysfunction in young male subjects with no additional cardiovascular risk factors, and reduction of tHcy by vitamin supplementation does not modify EDD in this age group." | ( Barrera, G; Bunout, D; Escobar, E; Gattas, V; Glasinovic, A; Hirsch, S; Petermann, M; Pia De la Maza, M; Yañez, P, 2002) |
| "Hyperhomocysteinemia is a common metabolic abnormality in patients undergoing hemodialysis (HD)." | ( Hsieh, BS; Huang, JW; Pai, MF; Tsai, TJ; Wu, KD; Yen, CJ, 2002) |
| "Hyperhomocysteinemia is an accepted risk factor for coronary artery disease, but the determining factors are not fully understood." | ( Herrmann, W; Jouma, M; Obeid, R, 2003) |
| "Although hyperhomocysteinemia is an independent risk factor for cardiovascular disease, a direct role for homocysteine (Hcy) in this disease remains to be shown." | ( Berger, PB; Durante, W; Gaubatz, JW; Jiang, X; Ma, L; Magera, MJ; Pownall, HJ; Schafer, AI; Wang, H; Yang, F; Yang, X, 2003) |
| "Hyperhomocysteinemia is recognized as an independent risk factor for premature atherosclerosis and venous thrombosis." | ( Akcakus, M; Halici, C; Karaküçük, I; Narin, F; Narin, N; Ustdal, M, 2002) |
| "Hyperhomocysteinemia is a risk factor for vascular disease and potentially for dementia and depression." | ( Diaz-Arrastia, R; Frol, AB; Rogers, JD; Sanchez-Saffon, A, 2003) |
| "Hyperhomocysteinemia is associated with an increased risk of vascular disease, and recent results suggest that it also could increase the risk of dementia." | ( Alpérovitch, A; Ducros, V; Dufouil, C; Tzourio, C, 2003) |
| "Hyperhomocysteinemia is a vascular risk factor that infers with the nitric oxide signaling pathway of endothelial vasoregulation." | ( Auch, D; Kaps, M; Osthaus, S; Rosengarten, B, 2003) |
| "Hyperhomocysteinemia is associated with endothelial dysfunction, although the underlying mechanism is unknown." | ( Cuniberti, LA; Dominguez, GN; Fischer, PA; Martinez, V; Masnatta, LD; Ramirez, AJ; Werba, JP, 2003) |
| "Hyperhomocysteinemia is an independent cardiovascular risk factor that possibly accounts for about one of 5 cardiovascular deaths." | ( Acantora, F; Cesare, CM; De Santo, NG; Ingrosso, D; Lombardi, C; Perna, AF; Satta, E, 2003) |
| "Studies have shown hyperhomocysteinemia is a risk factor for VTE, cerebrovascular disease, and coronary artery disease." | ( Frenkel, EP; Lee, R, 2003) |
| "Hyperhomocysteinemia is well documented in chronic renal failure (CRF) and premature and progressive occlusive vascular disease is common in CRF." | ( Calevo, MG; Canepa, A; Canini, S; Caridi, G; Carrea, A; Cerone, R; Dertenois, L; Minniti, G; Perfumo, F, 2003) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease in the general population." | ( Acanfora, F; Cesare, CM; De Santo, NG; Ingrosso, D; Lombardi, C; Perna, AF; Romano, MM; Satta, E; Violetti, E, 2003) |
| "In conclusion, hyperhomocysteinemia is associated with a 4-fold increased risk of cerebral vein thrombosis; whether or not its correction with vitamins reduces the risk of the disease remains to be demonstrated." | ( Battaglioli, T; Cattaneo, M; Mannucci, PM; Martinelli, I; Pedotti, P, 2003) |
| "Basal hyperhomocysteinemia is seen in approximately 50% of patients with cirrhosis and after OLT." | ( Bosy-Westphal, A; Czech, N; Fleig, W; Hinrichsen, H; Lotterer, E; Müller, MJ; Oehler, G; Plauth, M; Ruschmeyer, M, 2003) |
| "Hyperhomocysteinemia is a known and independent risk factor of atherosclerosis, occurring in 85-95% patients treated with hemodialysis." | ( Chmiel, G; Czarnecka, D; Drozdz, M; Gozdecka, H; Kowalczyk-Michałek, M; Kraśniak, A; Małczak, J; Miłkowski, A; Moskal, K; Podwysocki, A; Sułowicz, W; Sydor, A; Szczeklik, A; Szmigielski, M; Wiecek, A; Zabawa-Hołyś, S, 2002) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disease and accelerates atherosclerosis in apoE-/- mice." | ( Austin, RC; de Koning, AB; Dickhout, JG; Falk, E; Hossain, GS; Jacobsen, DW; Kaufman, RJ; Poddar, R; Sood, SK; Tang, D; van Thienen, JV; Werstuck, GH; Wu, D; Zhang, K; Zhou, J, 2003) |
| "Severe hyperhomocysteinemia is due to rare genetic defects resulting in deficiencies in CBS, MTHFR, or in enzymes involved in methyl cobalamine synthesis and homocysteine methylation." | ( Favier, A; Galan, P; Guilland, JC; Hercberg, S; Potier de Courcy, G, 2003) |
| "Hyperhomocysteinemia is a well-recognized independent risk factor for cardiovascular disease in end-stage renal disease (ESRD) patients." | ( Benedetti, S; Buoncristiani, E; Buoncristiani, U; Canestrari, F; Conte, C; Floridi, A; Galli, F; Piroddi, M, 2003) |
| "Although severe hyperhomocysteinemia is found in a number of inborn errors of metabolism, mild hyperhomocysteinemia is of concern because of its prevalence in the general population and its effect on the incidence of disease states." | ( Gilfix, BM, 2003) |
| "Moderate hyperhomocysteinemia is considered a risk factor for both venous and arterial thrombosis." | ( Abbate, R; Betti, I; Cappelli, S; Evangelisti, L; Fedi, S; Giusti, B; Marcucci, R; Menchini, U; Prisco, D; Sodi, A, 2003) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disease." | ( Blom, HJ; Boers, GH; Riksen, NP; Rongen, GA; Russel, FG; Smits, P, 2003) |
| "Hyperhomocysteinemia is becoming recognized as a risk factor for cardiovascular disease, yet there are limited data on the prevalence of hyperhomocysteinemia in patients with heart failure." | ( Aranda, JM; Cleeton, TS; Hill, JA; Schofield, RS; Walker, TC; Wessel, TR, 2003) |
| "Hyperhomocysteinemia is common in patients with severe heart failure, and plasma homocysteine levels are uniformly elevated regardless of the etiology of heart failure." | ( Aranda, JM; Cleeton, TS; Hill, JA; Schofield, RS; Walker, TC; Wessel, TR, 2003) |
| "Hyperhomocysteinemia is not linked with diabetic disease per se, rather fasting homocysteine plasma levels largely depend on glomerular filtration rate (GFR)." | ( Cucinotta, D; Russo, GT, 2003) |
| "Hyperhomocysteinemia is another risk factor for cardiovascular and cerebrovascular diseases, often exhibited by insulin-resistant patients." | ( Oron-Herman, M; Rosenthal, T; Sela, BA, 2003) |
| "Weak hyperhomocysteinemia is a risk factor for the development of atherothrombotic vascular complication." | ( Alonso, B; Benetucci, J; de Larrañaga, G; Puga, L, 2003) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases." | ( Au-Yeung, KK; O, K; Siow, YL; Sung, FL; Woo, CW; Yip, JC, 2004) |
| "Hyperhomocysteinemia is an independent cardiovascular risk factor that depends on folate and vitamin B12 nutrition." | ( Borzone, L; Cancino, M; Casanueva, V; Cid, L; Cid, X, 2003) |
| "Hyperhomocysteinemia is associated with alterations in vascular morphology, loss of endothelial anti-thrombotic function, and induction of a procoagulant environment." | ( Dierkes, J; Fowler, B; Geisel, J; Herrmann, W; Pietrzik, K; Stanger, O; Weger, M, 2003) |
| "Hyperhomocysteinemia is an established risk factor for atherosclerosis, thrombosis and other vascular diseases." | ( Frick, B; Fuchs, D; Leblhuber, F; Schroecksnadel, K; Winkler, C; Wirleitner, B, 2003) |
| "Hyperhomocysteinemia is an independent risk factor for the development of atherosclerosis." | ( Heydrick, SJ; Keaney, JF; Keller, C; Loscalzo, J; Postea, O; Weiss, N, 2003) |
| "Although hyperhomocysteinemia is an established risk factor for venous thromboembolism there is no consensus for routine determination of circulating homocysteine in the UK, either at the beginning or end of oral anticoagulation therapy." | ( Harrington, DJ; Kovacs, JA; Rangarajan, S; Savidge, GF; Shearer, MJ; Sobczyńska-Malefora, A, 2003) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disease (ischemic disease, such as stroke and myocardial infarction, and arterial and venous thrombotic events) in the general population." | ( De Santo, NG; Ingrosso, D; Perna, AF, 2003) |
| "Hyperhomocysteinemia is an emerging risk factor for cardiovascular disease and stroke." | ( Dayal, S; Lentz, SR; Rodionov, RN, 2003) |
| "Hyperhomocysteinemia is a potential risk factor for vascular disease and is associated with endothelial dysfunction, a predictor of adverse cardiovascular events." | ( Austen, SK; Coombes, JS; Fassett, RG, 2003) |
| "Hyperhomocysteinemia is a risk factor for premature atherosclerotic vascular disease and venous thrombosis." | ( Atabek, ME; Erkul, I; Pirgon, O, 2003) |
| "In 2/3 of cases hyperhomocysteinemia is caused by decreased levels of folic acid, pyridoxine, and cobalamin." | ( Graban, A, 2003) |
| "The results of hyperhomocysteinemia are increased risk of arteriosclerosis coronary heart diseases and stroke." | ( Bobkiewicz-Kozłowska, T; Chodera, A; Hertmanowska, H; Nowakowska, E, 2003) |
| "Hyperhomocysteinemia is often associated with an increase in blood pressure." | ( Berthelot, A; Courderot-Masuyer, C; Jacqueson, A; Nicod, L; Richert, L; Robin, S, 2004) |
| "Hyperhomocysteinemia is associated with arterial neointimal proliferation in subjects with homocystinuria, atherosclerosis and coronary graft disease." | ( Ambrosi, P, 2003) |
| "Hyperhomocysteinemia is probably a weak risk factor for coronary restenosis after angioplasty, although it is still difficult to ascertain whether homocysteine plays a causative role in restenosis." | ( Ambrosi, P, 2003) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease." | ( Andriolo, A; Franco, LJ; Gimeno, SG; Perez, AB; Sañudo, A; Tavares, EF; Vergani, N; Vieira-Filho, JP, 2004) |
| "Moderate hyperhomocysteinemia is a risk for neural tube defect and neurodegenerative and vascular diseases and has nutritional, metabolic, and genetic determinants." | ( Adjalla, CE; Amouzou, EK; Chabi, NW; Feillet, F; Guéant, JL; Rodriguez-Guéant, RM; Sanni, A; Villaume, C, 2004) |
| "Hyperhomocysteinemia is known to be associated with arterial occlusive vascular disease and venous thrombosis." | ( Albalushi, T; Alkindi, S; Bayoumi, R; Dennison, D; Muralitharan, S; Pathare, A, 2004) |
| "Hyperhomocysteinemia is common in Alzheimer's disease and is negatively correlated with cognitive function." | ( Arning, E; Bottiglieri, T; Hansen, LA; Kennedy, BP; Masliah, E; Ziegler, MG, 2004) |
| "Hyperhomocysteinemia is a frequent finding after cardiac transplantation, but increased folate intake induces a decrease in total homocysteine concentrations." | ( Cole, DE; Delgado, DH; Evrovski, J; Keren, ES; Langman, LJ; Mamer, OA; Miner, SE; Miriuka, SG; Ross, HJ, 2004) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disorders." | ( O, K; Siow, YL; Zhang, F, 2004) |
| "Mild hyperhomocysteinemia is associated with stiffer small arteries with increased collagen deposition in the media." | ( Amiri, F; Endemann, D; Neves, MF; Pu, Q; Rozen, R; Schiffrin, EL; Virdis, A, 2004) |
| "Hyperhomocysteinemia is associated with a 2-fold increased risk of recurrent venous thrombosis (RVT)." | ( Blom, HJ; Den Heijer, M; Heil, SG; Kluijtmans, LA; Van Der Rijt-Pisa, BJ, 2004) |
| "Hyperhomocysteinemia is a well-recognized risk factor for accelerated atherosclerosis in hemodialysis patients." | ( Abassi, Z; Brenner, B; Green, J; Khankin, E; Lanir, N; Nakhoul, F; Plawner, M; Ramadan, R, 2004) |
| "Hyperhomocysteinemia is a precursoral marker of systemic atherosclerosis and thus a prognostic indicator of cardiovascular morbidity and mortality in PAD." | ( Behrmann, C; Heins, S; Podhaisky, H; Taute, BM; Taute, R, 2004) |
| "Hyperhomocysteinemia is an emerging risk factor for stroke, but little is known about effects of hyperhomocysteinemia on cerebral vascular function." | ( Arning, E; Böger, RH; Bottiglieri, T; Dayal, S; Faraci, FM; Lentz, SR; Sigmund, CD, 2004) |
| "Hyperhomocysteinemia is associated with premature atherosclerosis and venous thromboembolism; so called "cholesterol of XXI." | ( Sztenc, S, 2004) |
| "Hyperhomocysteinemia is an important risk factor for atherosclerosis and it has recently been suggested as a diagnostic marker for Alzheimer disease (AD)." | ( De Valentin, L; Gallucci, M; Vianello, A; Zanardo, A, 2004) |
| "Hyperhomocysteinemia is a risk factor for dementia but only scanty data exist about its relationship to specific cognitive abilities during normal aging." | ( Bianchin, M; Forti, P; Maioli, F; Mantovani, V; Ravaglia, G; Saccheitti, L; Scali, RC; Talerico, T, 2004) |
| "Hyperhomocysteinemia is a risk factor for thrombosis, and methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms, folate, and B12 levels could contribute to plasma homocysteine (Hcy) variation." | ( Aléssio, AC; Annichino-Bizzacchi, JM; Bydlowski, SP; Eberlin, MN; Höehr, NF; Vellasco, AP, 2004) |
| "Hyperhomocysteinemia is associated with alterations in vascular morphology, loss of endothelial antithrombotic function, and induction of a procoagulant environment." | ( Dierkes, J; Fowler, B; Geisel, J; Herrmann, W; Pietrzik, K; Stanger, O; Weger, M, 2004) |
| "Although mild hyperhomocysteinemia is a risk factor for cardiovascular events and mortality, there is no evidence to suggest that mild hyperhomocysteinemia stimulates coronary artery atherosclerosis formation." | ( Black, MJ; Buxton, BF; Hare, DL; Zulli, A, 2004) |
| "Hyperhomocysteinemia is a metabolic syndrome based on interaction between genetic factors (most frequently 677C/T polymorphism of methylentetrahydrofolate reductase), diseases and demographic factors (smoking, aging, hormonal and nutritional factors)." | ( Zák, A; Zeman, M, 2004) |
| "Hyperhomocysteinemia is associated with decreased vascular reactivity and increased cardiovascular morbidity." | ( Asmis, R; Haefeli, WE; Linder, L; Litynsky, P; Nyfeler, J; Romerio, SC; Wenk, M, 2004) |
| "Hyperhomocysteinemia is an independent risk factor for atherothrombotic cerebral stroke." | ( Canbulat, CE; Ince, N; Kocer, A; Sargin, M, 2004) |
| "Hyperhomocysteinemia is associated with aging, endothelial dysfunction, and increased risk of coronary heart disease in older adults; however, the effects of homocysteine-lowering therapy on vascular reactivity in older persons are unknown." | ( Aeschlimann, SE; Carlsson, CM; Mitchell, C; Pharo, LM; Stein, JH; Underbakke, G, 2004) |
| "Hyperhomocysteinemia is able to promote glomerular damage and generate tubulointerstitial lesions." | ( Caram, SG; Dominguez, GN; Fischer, PA; Masnatta, LD; Monserrat, AJ; Ossani, GP, 2004) |
| "Hyperhomocysteinemia is a risk factor for atherosclerotic vascular diseases." | ( Guldiken, S; Kilic-Okman, T; Kucuk, M, 2004) |
| "Hyperhomocysteinemia is associated with an enhanced risk for cardiovascular disease." | ( Arakawa, N; Bode-Böger, SM; Böger, RH; Hornig, B; Münzel, T; Sydow, K; Tsikas, D, 2004) |
| "Hyperhomocysteinemia is a risk factor in obstetrical complications such as pre-eclampsia, 'hemolysis, elevated liver enzymes, low platelet' (HELLP)-syndrome and placental insufficiency." | ( Geisel, J; Herrmann, W; Hübner, U; Koch, I; Obeid, R; Retzke, U, 2004) |
| "Hyperhomocysteinemia is present in the majority of chronic hemodialysis patients." | ( De Bacquer, D; De Vriese, AS; Delanghe, JR; Geerolf, I; Lameire, NH; Langlois, M; Stevens, L; Taes, YE, 2004) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disorders." | ( Choy, PC; Minuk, GY; Mymin, D; O, K; Pierce, GN; Siow, YL; Woo, CW, 2005) |
| "Hyperhomocysteinemia is an ideal target as this parameter can be lowered easily, safely and at a low cost by means of folate and B-vitamin supplementation." | ( Stanger, O, 2004) |
| "Hyperhomocysteinemia is related to chronic complication in 2 diabetes mellitus, possibly due to the injury to the vascular endothelium by homocysteine." | ( Li, W; Li, WP; Yang, T, 2005) |
| "Hyperhomocysteinemia is partly amenable to correction by vitamin supplementation in CKD stages 3 and 4." | ( Beck, GJ; Greene, T; Kusek, JW; Levey, AS; Menon, V; Sarnak, MJ; Selhub, J; Wang, X, 2005) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease, dementia and depression." | ( Hase, K; Sakuta, H; Suzuki, T; Wakiyama, H; Yasuda, H, 2005) |
| "Hyperhomocysteinemia is not rare in male Japanese gastrectomized patients." | ( Hase, K; Sakuta, H; Suzuki, T; Wakiyama, H; Yasuda, H, 2005) |
| "(1) Hyperhomocysteinemia is found in most SLE, RA, AS and uSpA patients." | ( Li, XF; Wang, LY; Xiao, CS; Xu, XY; Zhou, WH, 2005) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases." | ( Chang, L; Du, JB; Geng, B; Tang, CS, 2005) |
| "Hyperhomocysteinemia is frequent in patients treated with antiepileptic drugs." | ( de la Peña, P; Fernández-Miranda, C; Gómez de la Cámara, A; Gómez, P; Penas, M; Saiz, R, 2005) |
| "Hyperhomocysteinemia is associated with an increased risk of venous and arterial thrombosis, probably by inducing endothelial damage." | ( Amato, S; Bottini, F; Calevo, MG; Cerone, R; Minniti, G; Molinari, AC; Perutelli, P, 2005) |
| "Hyperhomocysteinemia is not only a major risk factor for atherothrombotic disease, but is also strongly associated with an increased risk of dementia and cognitive impairment, both of which are common in the course of Parkinson's disease (PD)." | ( Benetin, J; Blazícek, P; Gmitterová, K; Kukumberg, P; Valkovic, P; Valkovicová, L, 2005) |
| "Hyperhomocysteinemia is frequent in newly diagnosed GSE." | ( Cattaneo, M; De Franchis, R; Formenti, S; Lecchi, A; Meucci, G; Rondonotti, E; Saibeni, S; Tagliabue, L; Vecchi, M, 2005) |
| "Hyperhomocysteinemia is a well known risk factor for the diseases of the cardiovascular system, which seem to be the main cause of increased mortality in patients with type 2 diabetes." | ( Kinalska, I; Kowalska, I; Rudy, A; Straczkowski, M, 2005) |
| "Moderate hyperhomocysteinemia is common in chronic alcoholics, mainly in those with liver damage, suggesting that, although folate deficiencies may have a contributory role, liver impairment, through changes in methionine metabolism, is the most important mechanism for the elevated plasma Hcy found in these patients." | ( Blasco, C; Caballería, J; Deulofeu, R; Gual, A; Lligoña, A; Lluis, JM; Parés, A; Rodés, J, 2005) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis and vascular disease; however, the mechanism underlying this association remains poorly understood." | ( Blom, HJ; Castro, R; Clode, N; de Almeida, IT; Graça, LM; Jakobs, C; Jansen, EE; Martins, C; Rivera, I; Struys, EA, 2005) |
| "To ascertain if hyperhomocysteinemia is associated with the metabolic syndrome." | ( Abouzahir, A; Baigts, F; Bauduceau, B; Bordier, L; Burnat, P; Dupuy, O; Garcin, JM; Gardet, V; Mayaudon, H, 2005) |
| "Hyperhomocysteinemia is considered a risk factor for vascular disease causing endothelial damage and consequently atherogenesis." | ( Bostantjopoulou, S; Frangia, T; Hatzizisi, O; Katsarou, Z; Kazis, A; Kiosseoglou, G; Kyriazis, G; Papazisis, K, 2005) |
| "Severe hyperhomocysteinemia is typically caused by rare enzymatic defects or by renal failure." | ( de Groot, LC; Verhoef, P, 2005) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease and stroke." | ( Lentz, SR; Wilson, KM, 2005) |
| "Hyperhomocysteinemia is common in patients with conventional HD schedules and this is not related to vitamin deficiencies." | ( Alvarez González, A; Delgado, P; Hernández, D; Lorenzo, V; Pérez Tamajón, L; Sánchez Alvarez, JE, 2005) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular diseases, while tissue factor pathway inhibitor (TFPI) regulates the extrinsic pathway of blood coagulation." | ( Götting, C; Kleesiek, K; Siegling, S; Thyzel, E, 2005) |
| "Hyperhomocysteinemia is a risk factor for a range of neurodegenerative conditions, yet its effects in the developing nervous system have been poorly elucidated." | ( Doherty, GH; Foister, NS; Mackie, JB; Oldreive, CE, 2005) |
| "Hyperhomocysteinemia is recognized as an independent risk factor for arterial disease including coronary artery disease, cerebrovascular disease and peripheral vascular disease." | ( Basar, N; Bicer, A; Erbay, AR; Sahin, O; Turhan, H; Yasar, AS; Yetkin, E, 2005) |
| "Hyperhomocysteinemia is defined as plasma homocysteine levels above the 95th percentile of the control subjects (13." | ( Basar, N; Bicer, A; Erbay, AR; Sahin, O; Turhan, H; Yasar, AS; Yetkin, E, 2005) |
| "Hyperhomocysteinemia is now regarded as one of the important risk factors for cardiovascular and cerebralvascular disorders." | ( Chen, J; Feng, YB; Gu, X; Li, M; Li, YS; Shi, CZ, 2006) |
| "Hyperhomocysteinemia is a common phenomenon among elderly people." | ( Chen, JH; Hashmi, A; Kuo, HK; Lipsitz, LA; Milberg, WP; Sorond, FA, 2005) |
| "Hyperhomocysteinemia is present in 15." | ( Ausserer, B; Graninger, G; Hubmann, M; Huemer, C; Huemer, M; Schlachter, K; Simma, B; Tscharre, A; Ulmer, H, 2005) |
| "Hyperhomocysteinemia is present in the majority of well-nourished chronic renal failure and uremic patients." | ( Acanfora, F; Capasso, R; Ingrosso, D; Lombardi, C; Perna, AF; Satta, E, 2005) |
| "hyperhomocysteinemia is associated with IBD and low folate levels, and could be involved in development of thromboembolism." | ( Casis Herce, B; Fernández-Miranda, C; Gómez de la Cámara, A; Gómez González, P; Martínez López, J; Martínez Prieto, M; Sáenz-López Pérez, S; Sánchez Gómez, F, 2005) |
| "Hyperhomocysteinemia is associated with cerebral small vessel disease (SVD)." | ( Fan, YH; Lam, WW; Liang, KS; Mok, V; Wong, A; Wong, KS, 2006) |
| "Hyperhomocysteinemia is associated with volumetric measure of WMC among patients with SVD." | ( Fan, YH; Lam, WW; Liang, KS; Mok, V; Wong, A; Wong, KS, 2006) |
| "Hyperhomocysteinemia is currently considered a relatively weak prothrombotic factor." | ( Brozek, J; Szczeklik, A; Undas, A, 2005) |
| "Hyperhomocysteinemia is a strong risk factor for all-cause and CV mortality in hemodialysis patients who do not present CIMS." | ( Chalopin, JM; Devillard, N; Ducloux, D; Kazory, A; Klein, A, 2006) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease in the general population, but in end-stage renal disease patients some studies show a reverse association, i." | ( Bárány, P; Lindholm, B; Rashid Qureshi, A; Stenvinkel, P; Suliman, ME, 2006) |
| "Hyperhomocysteinemia is considered as one of the risk factors for venous thrombosis." | ( den Heijer, M, 2006) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease and stroke." | ( Dayal, S; Lentz, SR, 2005) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disorders." | ( O, K; Siow, YL; Woo, CW, 2006) |
| "Treatment of hyperhomocysteinemia is primarily through vitamin supplementation; folic acid and vitamins B(6) and B(12) are the mainstay of therapy." | ( Guthikonda, S; Haynes, WG, 2006) |
| "Hyperhomocysteinemia is common in high-risk women and adversely affects their prognosis, although it is unrelated to the CAD atherosclerotic burden." | ( Burlina, A; Cesari, M; Maiolino, G; Pedon, L; Pessina, AC; Rossi, GP; Seccia, TM; Sticchi, D; Zanchetta, M; Zavattiero, S, 2006) |
| "We conclude that hyperhomocysteinemia is associated with a decreased activity and expression of CBS in renal PTs because of the defect of chromosome 13 in SS rats." | ( Chen, L; Li, N; Li, PL; Muh, RW, 2006) |
| "Moderate hyperhomocysteinemia is an independent risk factor for cardiovascular disease (CVD) even among children." | ( Arvanitidou, M; Makedou, A; Mavromichalis, I; Papandreou, D; Rousso, I, 2006) |
| "Hyperhomocysteinemia is consistently associated with cognitive decline." | ( Bell, RJ; Davis, SR; Shah, S, 2006) |
| "Hyperhomocysteinemia is a risk factor for thromboembolic vasculopathy in patients with PEXS and PEXG." | ( Hasiripi, H; Karakurt, A; Saricaoglu, MS; Sengun, A, 2006) |
| "In conclusion, hyperhomocysteinemia is associated with the duration of PD and levodopa treatment and possibly also with PD per se." | ( Barcikowska, M; Chodakowska-Zebrowska, M; Czyzewski, K; Lokk, J; Peplonska, B; Religa, D; Stepien, K; Styczynska, M; Winblad, B, 2006) |
| "Hyperhomocysteinemia is a modifiable risk factor for osteoporosis and its related bone fractures." | ( Kim, DJ; Kim, GS; Kim, HH; Kim, YS; Koh, JM; Lee, KU; Lee, YS; Park, JY, 2006) |
| "Hyperhomocysteinemia is a known risk factor for development of cardiovascular disease, vascular dementia, depression, and possibly some carcinogeneses." | ( Akoglu, B; Caspary, WF; Faust, D; Wondra, K, 2006) |
| "Hyperhomocysteinemia is a known risk factor for cardiovascular diseases, but the underlying mechanisms of this pathology are complex." | ( Cunha, FQ; de Andrade, CR; de Godoy, MA; de Oliveira, AM; de Souza, HP; Eberlin, MN; Fukada, SY; Haddad, R; Laurindo, FR; Olivon, VC, 2006) |
| "Hyperhomocysteinemia is also found in patients with liver diseases." | ( O, K; Prathapasinghe, GA; Siow, YL; Woo, CW, 2006) |
| "Whether mild hyperhomocysteinemia is a risk factor for ischemic heart disease (IHD) or it is a secondary epiphenomenon remains unknown." | ( Assanelli, D; Grassi, M; Pezzini, A, 2007) |
| "Hyperhomocysteinemia is known to be a risk factor for cardiovascular diseases and is associated with a common mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (677 C>T)." | ( Cho, SE; Chung, WS; Hong, KS; Shin, GJ, 2006) |
| "Hyperhomocysteinemia is known as an independent risk factor of atherosclerosis, but the probable role of hyperhomocysteinemia in premature Coronary Artery Disease (CAD) is not well studied." | ( Darvish, S; Davoodi, G; Fallah, N; Fallahi, F; Karimi, A; Mahmoodian, M; Sadeghian, S; Salarifar, M, 2006) |
| "Hyperhomocysteinemia is a risk factor for venous thrombosis, but the underlying mechanism is unclear." | ( Blom, HJ; Borm, GF; den Heijer, M; Hermus, AR; Keijzer, MB; Ueland, PM; Vollset, SE, 2006) |
| "Hyperhomocysteinemia is a known marker, and probably risk factor for stroke, fostering atherosclerosis and thrombosis." | ( Boughanem, N; Leemann, B; Schnider, A, 2006) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerotic vascular disease in chronic hemodialysis patients." | ( Chaiyasoot, W; Chanchairujira, T; Leowattana, W; Ong-ajyooth, L; Ong-ajyooth, S; Shayakul, C; Sritippayawan, S; Tungkasereerak, P; Vareesangthip, K; Vasuvattakul, S, 2006) |
| "Moderate hyperhomocysteinemia is one of risk factors for arteriosclerotic disease." | ( Araki, A, 2006) |
| "As hyperhomocysteinemia is a strong risk factor for adult cardiovascular disease, these data may imply that the hyperhomocysteinemic mothers and their children should be targeted for nutritional interventions." | ( de Jonge, R; de Vries, JH; Hop, WC; Steegers-Theunissen, RP; Ursem, NT; Verkleij-Hagoort, AC, 2006) |
| "Hyperhomocysteinemia is considered an independent risk factor for vascular occlusive diseases." | ( Castañon, MM; Kordich, L; Lauricella, AM; Quintana, I, 2007) |
| "Moderate hyperhomocysteinemia is a complex trait commonly associated with inflammatory bowel disease (IBD)." | ( Bigard, MA; Bronowicki, JP; Chamaillard, M; Desreumaux, P; Guéant, JL; Peyrin-Biroulet, L; Rodriguez-Guéant, RM; Xia, B, 2007) |
| "The causes of hyperhomocysteinemia are multifactorial, such as genetic defects, pathophysiological conditions, lifestyle and drugs-related." | ( Bendini, MG; Cozzari, L; De Cristofaro, R; Farina, SM; Giordano, A; Giordano, G; Lanza, GA; Leggio, M; Mazza, A; Menichini, G; Moriconi, E, 2007) |
| "Hyperhomocysteinemia is frequent in the Caucasian population (more than 15%) and its role in vascular pathology has been clearly established." | ( Pofelski, J; Roblin, X; Zarski, JP, 2007) |
| "Hyperhomocysteinemia is associated with an increase in the incidence of vascular diseases, including retinal vascular diseases." | ( Chae, EH; Chang, N; Kim, JM; Kim, SJ; Lee, H; Lee, I, 2007) |
| "Hyperhomocysteinemia is a described risk factor of cardiovascular diseases." | ( Akoglu, B; Bolouri, H; Caspary, WF; Faust, D; Jaffari, A; Kutschera, E; Schrott, M, 2008) |
| "Severe hyperhomocysteinemia is associated with atherosclerosis." | ( Caprini, JA; Eldibany, MM, 2007) |
| "Whether hyperhomocysteinemia is a cardiovascular risk factor or is just an epiphenomenon is a subject of debate." | ( Kothekar, MA, 2007) |
| "Hyperhomocysteinemia is a recognized risk factor for vascular disease, but pathogenetic mechanisms involved in its vascular actions are largely unknown." | ( Ancora, MA; Carluccio, M; Carluccio, MA; De Caterina, R; Distante, A; Massaro, M; Scoditti, E; Storelli, C, 2007) |
| "Hyperhomocysteinemia is a risk factor for ischemic stroke." | ( Arlier, Z; Benli, S; Karaca, S; Karakurum Goksel, B; Karatas, M; Nebioglu, A; Seydaoglu, G; Sezgin, N; Tan, M; Yerdelen, D, 2007) |
| "Hyperhomocysteinemia is a well-established risk factor for cardiovascular diseases." | ( Angeli, A; Borrione, P; Massazza, G; Paccotti, P; Pigozzi, F; Schonhuber, H; Viberti, G, 2007) |
| "Hyperhomocysteinemia is an accepted risk factor for cardiovascular disease, and possibly also for cognitive impairment and dementia." | ( Albers, U; Alder, M; Barrios, L; Castillo, MJ; Gonzalez-Gross, M; Pietrzik, K; Sola, R, 2007) |
| "Hyperhomocysteinemia is considered an independent risk factor for atherosclerosis." | ( Chandra, R; Rai, SK; Sharma, M; Tiwari, M, 2007) |
| "Moderate hyperhomocysteinemia is a risk factor for neurodegenerative diseases and complications during pregnancy." | ( Baydas, G; Etem, E; Koz, ST; Nedzvetsky, VS; Tuzcu, M, 2007) |
| "Hyperhomocysteinemia is now well established as an independent risk factor for atherosclerotic vascular disease." | ( Hasegawa, H; Hashimoto, T; Shinohara, Y, 2007) |
| "Hyperhomocysteinemia is one of the factors that have been related to thromboembolic complications." | ( Majluf-Cruz, A; Montano-Loza, A; Uscanga, L; Vargas-Vorackova, F; Zapata-Colindres, JC; Zepeda-Gómez, S, 2008) |
| "We conclude that hyperhomocysteinemia is common in women with advanced breast cancer." | ( Burcombe, RJ; Cladd, H; Cooper, P; Gatt, A; Makris, A; Makris, M; Smith, JM; Thompson, D, 2007) |
| "Hyperhomocysteinemia is characterized by abnormally high concentrations of homocysteine (Hcy) in the plasma." | ( O, K; Siow, YL; Woo, CWH, 2008) |
| "Maternal hyperhomocysteinemia is associated with congenital heart defects (CHDs) in the offspring." | ( Helbing, WA; Isaacs, A; Lindemans, J; Steegers, EA; Steegers-Theunissen, RP; Uitterlinden, AG; van Driel, LM; Verkleij-Hagoort, AC, 2008) |
| "Hyperhomocysteinemia is associated with Alzheimer's disease, and has been hypothesized to promote neurodegeneration, by inhibiting brain methylation activity." | ( Calamandrei, G; Cavallaro, RA; Coluccia, P; D'Anselmi, F; Fuso, A; Nicolia, V; Ricceri, L; Scarpa, S, 2008) |
| "Hyperhomocysteinemia is common in Kuwaiti patients with CVA and tHcy probably interacts with prothrombotic factors (protein C, APC-R and factor VIII) to increase CVA risk." | ( Abdella, NA; Al Humood, S; Al Shayeb, AR; Al Wazzan, H; El-Muzaini, H; Marouf, R; Mojiminiyi, OA; Qurtom, M; Samad, MA, 2008) |
| "Chronic hyperhomocysteinemia is a risk factor in cardiovascular diseases and neurodegeneration." | ( Baydas, G; Koz, ST; Nedzvetsky, VS; Tuzcu, M, 2008) |
| "Hyperhomocysteinemia is frequently observed in alcohol-dependent subjects, in particularly in those with marked withdrawal symptoms." | ( Benyamina, A; Debuire, B; Karila, L; Lemoine, A; Marill, C; Pham, P; Reffas, M; Reynaud, M; Saffroy, R, 2008) |
| "Hyperhomocysteinemia is frequently observed in alcohol-dependent subjects, particularly in those with marked withdrawal symptoms." | ( Benyamina, A; Debuire, B; Karila, L; Lemoine, A; Marill, C; Pham, P; Reffas, M; Reynaud, M; Saffroy, R, 2008) |
| "Hyperhomocysteinemia is due to genetic and acquired factors (unhealthy lifestyle with poor diet in folate and vitamin B, elderly, renal impairment, thyroid diseases, malignancies)." | ( Andercou, A; Hoţoleanu, C; Porojan-Iuga, M; Rusu, ML, 2007) |
| "Hyperhomocysteinemia is associated with an increased risk of cognitive impairment in the elderly." | ( Ducros, V; Dufouil, C; Tzourio, C; Vidal, JS, 2008) |
| "Hyperhomocysteinemia is a well-known independent marker factor for atherothrombotic diseases and may result from acquired and genetic influences." | ( Abbate, R; Bolli, P; Gensini, GF; Giusti, B; Gori, AM; Magi, A; Marcucci, R; Saracini, C; Sestini, I; Sticchi, E, 2008) |
| "Hyperhomocysteinemia is among the factors incriminated in RA-associated atheroma." | ( El Bouchti, I; Kuntz, JL; Sibilia, J; Sordet, C, 2008) |
| "Hyperhomocysteinemia is a risk factor for arterial and venous thrombosis." | ( Aixalá, M; Alberto, MF; Casais, P; Lazzari, MA; Meschengieser, SS; Salviú, MJ, 2009) |
| "Hyperhomocysteinemia is an established risk factor for arterial as well as venous thromboembolism." | ( Dayal, S; Lentz, SR, 2008) |
| "Hyperhomocysteinemia is an independent risk factor for coronary artery disease (CAD)." | ( Cheng, CH; Huang, MC; Huang, YC; Lee, BJ; Lin, PT; Tsai, TP, 2008) |
| "Hyperhomocysteinemia is known as an independent-risk factor for coronary-artery disease (CAD)." | ( Belkahla, R; Ben Abdelaziz, A; Ben Hadj Mbarek, I; Ben Rejeb, N; Boughzala, E; Bouslama, A; Kchok, K; Nabli, N; Omezzine, A; Rebhi, L; Rejeb, J; Slimane, N, 2008) |
| "Hyperhomocysteinemia is a potentially modifiable risk factor for stroke, and may have a negative impact on the course of ischaemic stroke." | ( Adeyomoye, AA; Awosanya, GO; Danesi, MA; Okubadejo, NU; Oladipo, OO, 2008) |
| "In conclusion, hyperhomocysteinemia is associated with pre-eclampsia as well as eclampsia, but in eclampsia the severity of homocysteine elevation is more compared to that in pre-eclampsia." | ( Bulbul, T; Ferdausi, M; Hoque, MM; Islam, NA; Mahal, M, 2008) |
| "Hyperhomocysteinemia is an independent risk factor for premature cardiovascular disease." | ( Cabarkapa, V; Ilincić, B; Stosić, Z; Zeravica, R, 2007) |
| "Hyperhomocysteinemia is characterized by an increase of plasma homocysteine, a thiol-containing amino acid produced during methionine metabolism." | ( Belin, N; Delabar, JM; Ducros, V; Hamelet, J; Janel, N; Noll, C; Paul, JL, 2009) |
| "Moderate hyperhomocysteinemia is associated with many diseases." | ( Cao, J; Hanson, NQ; Kim, Y; Loria, CM; Schreiner, PJ; Siscovick, D; Tsai, MY, 2009) |
| "While hyperhomocysteinemia is associated with an increased risk of cardiovascular diseases, the effect of hyperhomocysteinemia on the vascular adventitia and vessel remodeling has not been clearly demonstrated." | ( Chen, FY; Chen, L; Gao, W; Guo, YH; Wang, GS, 2008) |
| "Hyperlipidemia and hyperhomocysteinemia are regarded as major risk factors for cardiovascular disease." | ( Choi, YM; Choue, R; Lim, HJ, 2008) |
| "We found that hyperhomocysteinemia is an independent risk factor (p=0." | ( Banecka-Majkutewicz, Z; Banecki, B; Jakóbkiewicz-Banecka, J; Kadziński, L; Nyka, W; Sawuła, W; Wegrzyn, G, 2009) |
| "Hyperhomocysteinemia is found in 60." | ( Bansal, V; Kalita, J; Kumar, G; Misra, UK, 2009) |
| "Hyperhomocysteinemia is associated with an increased risk of cardiovascular diseases." | ( Achour, A; Kerkeni, M; Letaief, A; Maaroufi, K; Miled, A; Trivin, F, 2009) |
| "Hyperhomocysteinemia is considered an independent cardiovascular risk factor, although the most recent intervention studies utilizing folic acid are negative." | ( Ingrosso, D; Perna, AF, 2009) |
| "Hyperhomocysteinemia is associated with an increased risk of atherosclerosis and cardiovascular disease." | ( Elmadfa, I; Singer, I, 2009) |
| "Hyperhomocysteinemia is a known marker, and probably a risk factor, for stroke, fostering atherosclerosis and thrombosis." | ( Basir, A; Bougteba, A; Kissani, N, 2009) |
| "Hyperhomocysteinemia is a well-defined risk factor for endothelial dysfunction and atherosclerosis." | ( Eminagaoglu, S; Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karahan, C; Kocak, M; Ukinc, K; Yilmaz, M, 2009) |
| "Hyperhomocysteinemia is a risk factor for a number of cardiovascular and neurodegenerative processes as well as a complicating factor in normal pregnancy." | ( Boldyrev, AA, 2009) |
| "Since hyperhomocysteinemia is considered an important cardiovascular risk factor, it could also be involved in the pathogenesis of ED." | ( Culasso, F; Dondero, F; Gandini, L; Jannini, EA; Lenzi, A; Lombardo, F; Piroli, E; Tsamatropoulos, P, 2010) |
| "The treatment of hyperhomocysteinemia is based on food supplements and medication, with folic acid and vitamins B6 and B12." | ( Melo, SS; Vannucchi, H, 2009) |
| "Hyperhomocysteinemia is correlated with diseases and lifestyle habits." | ( Kuriyama, N; Mitani, S; Mizuno, T; Ozaki, E; Ozasa, K; Shigeta, M; Watanabe, Y; Yokota, S, 2010) |
| "Hyperhomocysteinemia is associated with an increased risk of several complex diseases, including cardiovascular diseases." | ( Chmurzynska, A; Malinowska, A, 2009) |
| "Hyperhomocysteinemia is emerging as an independent predictor of cardiovascular disease and hypertension among children." | ( Arvanitidou, M; Makedou, A; Malindretos, P; Papandreou, D; Rousso, I, 2010) |
| "Hyperhomocysteinemia is a risk factor of changes in coagulation cascade through direct cytotoxic influence on endothelium, atherogenesis, activation of coagulation factor V and VII, increased level of thrombin and platelets aggregation." | ( Barlik, M; Drews, K; Kurzawińska, G; Mrozikiewicz, PM; Seremak-Mrozikiewicz, A, 2009) |
| "Hyperhomocysteinemia is observed in approximately 5% of the general population and is associated with an increased risk for many disorders, including vascular and neurodegenerative diseases, autoimmune disorders, birth defects, diabetes, renal disease, osteoporosis, neuropsychiatric disorders, and cancer." | ( Brustolin, S; Félix, TM; Giugliani, R, 2010) |
| "Hyperhomocysteinemia is a cardiovascular risk factor that is associated with elevation of the nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA)." | ( Arning, E; Baumbach, GL; Bottiglieri, T; Cooke, JP; Dayoub, H; Faraci, FM; Kimoto, M; Lentz, SR; Lynch, CM; Murry, DJ; Rodionov, RN; Stevens, JW; Wilson, KM, 2010) |
| "Anemia and hyperhomocysteinemia are risk factor of mortality of patients on dialysis." | ( Anees, M; Asghar, A; Ibrahim, M; Mumtaz, A; Shaheen, SM, 2010) |
| "Hyperhomocysteinemia is a risk factor for ischemic heart disease." | ( Alter, P; Figiel, JH; Klose, KJ; Maisch, B; Renz, H; Rominger, MB; Rupp, H, 2010) |
| "Maternal hyperhomocysteinemia is associated with a number of complications such as preeclampsia syndrome, thromboembolic events, repeated miscarriages, abruptio placentae, in utero fetal death, intrauterine fetal growth restriction and fetal neural tube defects." | ( Baydas, G; Demir, N; Etem, E; Gouwy, NT; Koz, ST; Nedzvetsky, VS, 2010) |
| "Hyperhomocysteinemia is associated with cerebro- and cardiovascular disease in industrialized countries, mostly resulting from protein rich diet and sedentary life style." | ( Gargoum, R; Maldonado, C; Metreveli, N; Rosenberger, D; Sen, U; Tyagi, N; Tyagi, S, 2011) |
| "Hyperhomocysteinemia is frequently observed in patients with diabetic nephropathy." | ( Cattran, DC; Churchill, DN; Dresser, GK; Eliasziw, M; Fine, A; House, AA; Oliver, MJ; Spence, JD, 2010) |
| "Hyperhomocysteinemia is a common and possibly modifiable risk factor that should be considered when screening patients with VTE." | ( Aydoğdu, M; Bukan, N; Ekim, N; Kanbay, A; Köktürk, N; Özyılmaz, E, 2011) |
| "Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders." | ( Kapoor, P; Khanna, S; Pillai, KK; Vohora, D, 2011) |
| "Hyperhomocysteinemia is also a risk factor for cardiovascular disease." | ( Au-Yeung, KK; House, J; Hwang, SY; O, K; Siow, YL, 2011) |
| "Hyperhomocysteinemia is a risk factor for cardiovascular disease, stroke, and thrombosis; however, the mechanisms by which homocysteine triggers these dysfunctions are not fully understood." | ( da Cunha, AA; da Cunha, MJ; Kolling, J; Scherer, EB; Wyse, AT, 2011) |
| "Hyperhomocysteinemia is a risk factor for neurodegeneration, and binding of copper by homocysteine is a putative underlying mechanism." | ( Farkas, M; Ineichen, B; Jelcic, I; Jung, H; Keskitalo, S; Kühnlein, P; Linnebank, M; Ludolph, AC; Petersen, J; Semmler, A; Weller, M, 2011) |
| "Hyperhomocysteinemia is common in patients with end-stage renal disease." | ( Ghorbani, R; Jamshidi, L; Malek, F; Malek, M; Soliemani, A; Tamadon, MR, 2011) |
| "Hyperhomocysteinemia is an independent risk factor that favors the occurrence of acute coronary syndromes in patients with coronary heart disease." | ( Chrostek, L; Cylwik, B, 2011) |
| "Hyperhomocysteinemia is a major risk factor for cerebral and peripheral vascular diseases, as well as cortical and hippocampal injury, including an increased risk of dementia and cognitive impairment." | ( Garlipp, CR; Gobbi, LT; Gobbi, S; Nascimento, CM; Santos, RF; Stella, F, 2011) |
| "In conclusion, hyperhomocysteinemia is independently associated with a greater risk of CIN in patients undergoing percutaneous coronary intervention." | ( Choi, D; Choi, KH; Han, SH; Hong, MK; Jang, Y; Kang, SW; Kim, BK; Kim, JS; Kim, SJ; Ko, YG; Yoo, TH, 2011) |
| "Hyperhomocysteinemia is associated with an increased risk of atherosclerotic and thromboembolic disorders, as well as hyperinsulinemia and may partially account for increased risk of cardiovascular disease associated with insulin resistance." | ( Grodnitskaya, EE; Kurtser, MA, 2012) |
| "Hyperhomocysteinemia is known to cause degeneration of retinal ganglion cells, but its influence on photoreceptors remains largely unknown." | ( Chang, HH; Chen, BY; Chen, YS; Lin, DP; Lin, W; Liu, HJ; Teng, MC; Tsao, ZJ, 2011) |
| "Hyperhomocysteinemia is associated with an increased risk of Alzheimer's disease (AD)." | ( Liu, GP; Liu, YH; Mousseau, DD; Tian, Q; Wang, JZ; Wang, Q; Wei, W; Wei, Z; Zhang, CE, 2011) |
| "Hyperhomocysteinemia is an independent risk factor for atherothrombotic disease and venous thrombosis." | ( Atilla, P; Bitik, O; Çalş, M; Ersoy, US; Kamburoğlu, HO; Öcal, E; Pnar, A; Şafak, T; Sönmez, E; Uzun, H, 2011) |
| "Since mild hyperhomocysteinemia is a risk factor for cardiovascular and cerebral diseases and extracellular nucleotides/nucleosides, which are controlled by the enzymatic action of ectonucleotidases, can induce an immune response, in the present study, we investigated the effect of chronic mild hyperhomocysteinemia on ectonucleotidase activities and expression in lymphocytes from mesenteric lymph nodes and serum of adult rats." | ( Bogo, MR; Bonan, CD; Ferreira, AG; Savio, LE; Scherer, EB; Vuaden, FC; Wyse, AT, 2012) |
| "High prevalence of hyperhomocysteinemia is common in hemodialysis (HD) patients and could contribute to worsen the cardiovascular risk." | ( Badiou, S; Bargnoux, AS; Bosc, JY; Canaud, B; Chalabi, L; Cristol, JP; Jaussent, I; Leray-Moragues, H; Morena, M; Rodriguez, A, 2011) |
| "Hyperhomocysteinemia is believed to induce endothelial dysfunction, which is an independent risk factor for atherosclerosis and vascular diseases." | ( Kang, RX; Zhang, JJ, 2012) |
| "Hyperhomocysteinemia is a risk factor of atherogenesis." | ( Chen, Y; Hammock, BD; Kong, W; Xie, X; Zhang, D; Zhu, Y, 2012) |
| "Hyperhomocysteinemia is a medical indicator of specific vessel stenosis in the Lebanese population." | ( Abchee, AB; Badro, DA; Cazier, JB; Chammas, E; Douaihy, B; el Bayeh, H; Gauguier, D; Ghassibe-Sabbagh, M; Haber, M; Hager, J; Kamatani, Y; Kibbani, S; Milane, A; Nemr, R; Othman, R; Platt, DE; Salloum, AK; Shasha, N; Stewart, K; Youhanna, S; Zalloua, PA, 2012) |
| "Hyperhomocysteinemia is a risk factor for neurological diseases, but the underlying pathophysiology has not been adequately explained." | ( Ben Abdallah, J; Charfeddine, B; Letaef, A; Limem, K; Naffeti, S; Othmen, LB; Smach, MA, 2013) |
| "Hyperhomocysteinemia is well recognized as an independent risk factor for the development of premature atherosclerosis." | ( Janel, N; Lameth, J; Noll, C; Paul, JL, 2013) |
| "Hyperhomocysteinemia is considered a risk factor for atherosclerosis." | ( Bereczky, Z; Csiki, Z; Katona, É; Shemirani, AH; Zsóri, KS, 2013) |
| "Frailty and hyperhomocysteinemia are common in the older population." | ( Almeida, OP; Flicker, L; Hankey, GJ; McCaul, KA; Wong, YY; Yeap, BB, 2013) |
| "Hyperhomocysteinemia is associated with the prevalence of frailty." | ( Almeida, OP; Flicker, L; Hankey, GJ; McCaul, KA; Wong, YY; Yeap, BB, 2013) |
| "Hyperhomocysteinemia is a risk factor for osteoporotic fractures." | ( Gamsjaeger, S; Klaushofer, K; Paschalis, EP; Rumpler, M; Spitzer, S; Thaler, R; Varga, F; Zwerina, J, 2013) |
| "Hyperhomocysteinemia is associated with Alzheimer's disease (AD)." | ( Bain, N; Blom, H; Farkas, M; Ineichen, B; Keskitalo, S; Kulic, L; Linnebank, M; Semmler, A; Smith, DE; Smulders, Y, 2013) |
| "Hyperhomocysteinemia is a risk factor for a number of neurodegenerative and cardiovascular diseases." | ( Boldyrev, A; Bryushkova, E; Mashkina, A; Vladychenskaya, E, 2013) |
| "Hyperhomocysteinemia is an independent risk factor for stroke and other vascular events." | ( Bopp, G; Hoefgen, B; Kallweit, U; Linnebank, M; Maier, W; Moskau, S; Schütz, CG; Semmler, A; Wüllner, U, 2012) |
| "Hyperhomocysteinemia is associated with inflammation and may be a risk marker for CRC." | ( Beresford, SA; Brown, EC; Cheng, TY; Green, R; Miller, JW; Neuhouser, ML; Rodriguez, B; Song, X; Ulrich, CM; Zheng, Y, 2013) |
| "Hyperhomocysteinemia is a risk factor for early-onset venous thrombosis." | ( Kim, GH; Kim, SJ; Kim, YM; Lee, BH; Yoo, HW, 2013) |
| "Some forms of hyperhomocysteinemia are treatable; thus a standardized and reliable diagnostic setting has to be at hand." | ( Denecke, J, 2013) |
| "Hyperhomocysteinemia is a risk factor for RVO." | ( Al Ali, M; Al Wadani, F; Khandekar, R; Ramzi, S; Salim, G, 2014) |
| "Hyperhomocysteinemia is associated with cognitive impairment in the middle-aged and the elderly persons in Tianjin." | ( Cheng, DM; Huang, CY; Jiang, YG; Kong, HY; Liu, J; Pang, W; Sun, SD, 2013) |
| "Hyperhomocysteinemia is a condition that results from altered methyl group metabolism and is associated with numerous pathological conditions." | ( Albright, KA; Neuman, JC; Schalinske, KL, 2013) |
| "Hyperhomocysteinemia is associated with an elevated cardiovascular disease risk." | ( Bailey, KR; Garovic, VD; Kardia, SL; Kullo, IJ; Mosley, TH; Turner, ST; White, WM; Wiste, HJ, 2013) |
| "Hyperhomocysteinemia is one of the risk factors inducing the onset of AD." | ( Cheng, YY; Hong, Y; Hou, Y; Li, YL; Niu, C; Yu, LX, 2013) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases." | ( Hou, DD; Huang, HX; Li, X; Liu, T; Liu, W; Wang, K; Wang, W; Xu, HB; Xu, JP; Zhang, H; Zhao, Q; Zhen, PP, 2013) |
| "Hyperhomocysteinemia is a well-recognized risk factor for cardiovascular disease; however, its association with ST use has never been investigated." | ( Iqbal, MP; Yakub, M, 2013) |
| "Hyperhomocysteinemia is a well-known risk factor for vascular disease." | ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| "Hyperhomocysteinemia is associated with arterial stiffness, but underlying pathophysiological mechanisms explaining this association are to be revealed." | ( Blom, H; Brouwer-Brolsma, EM; de Groot, LC; de Jongh, RT; Dhonukshe-Rutten, RA; Enneman, AW; Feskens, E; Geleijnse, JM; Ham, AH; Lips, P; Mattace-Raso, FU; Smulders, YM; Swart, KM; Uitterlinden, AG; van den Meiracker, AH; van der Velde, N; van der Zwaluw, NL; van Dijk, SC; van Meurs, J; van Schoor, NM; van Wijngaarden, JP, 2014) |
| "Hyperhomocysteinemia is strongly associated with cardiovascular diseases." | ( Liu, H; Liu, T; Liu, X; Lu, L; Ma, L; Song, D; Sun, Q; Wang, K; Wang, W; Zhang, H; Zhang, X; Zhen, P; Zuo, X, 2014) |
| "Hyperhomocysteinemia is a well-known modifiable risk factor for thromboembolism." | ( Desai, AR; Gore, AD; Gore, MA; Rao, GS, 2014) |
| "Hyperhomocysteinemia is significantly correlated with cardiovascular disease and its complications: heart attacks and strokes." | ( Baszczuk, A; Kopczyński, Z, 2014) |
| "Hyperhomocysteinemia is one of the important factors of the cardiovascular disease, and gout is well known to be associated with cardiovascular disease." | ( Choi, ST; Kim, JS; Song, JS, 2014) |
| "In conclusion, hyperhomocysteinemia is associated with carotid RI, a surrogate marker of cerebral vascular resistance, especially in elderly men." | ( Enomoto, D; Higaki, J; Irita, J; Kudo, K; Kukida, M; Miyoshi, K; Nagao, T; Okura, T; Pei, Z; Tanino, A, 2014) |
| "Hyperhomocysteinemia is often associated with liver and metabolic diseases." | ( da Costa, KA; Fiorucci, S; Goedken, MJ; Guo, G; Jaeschke, H; Kong, B; Lebofsky, M; Lee, S; Orena, SJ; Renga, B; Rudraiah, S; Smalling, R; Tsuchiya, H; Wang, L; Yang, Z; Zeisel, SH; Zhang, Y, 2015) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disease." | ( Huang, H; Huang, W; Ling, W; Peng, C; Su, X; Wu, X; Xia, M; Xiao, Y; Zhang, J, 2015) |
| "Hyperhomocysteinemia is associated with increased cardiovascular risk, but treatment with folic acid has no effect on outcome in unselected patient populations." | ( Asmer, I; Barak, M; Cassel, A; Flugelman, MY; Karkabi, B; Karkabi, K; Remer, E; Rozenberg, O; Shiran, A; Zittan, E, 2015) |
| "Hyperhomocysteinemia is an important cardiovascular risk indicator in the oldest old, and is associated with elevated arterial stiffness in this age group." | ( Blom, HJ; Brouwer-Brolsma, EM; de Groot, LC; de Jongh, RT; Dhonukshe-Rutten, RA; Enneman, AW; Feskens, EJ; Geleijnse, JM; Ham, AC; Lips, P; Mattace Raso, FU; Smulders, YM; Swart, KM; Uitterlinden, AG; van den Meiracker, AH; van der Velde, N; van der Zwaluw, NL; van Dijk, SC; van Schoor, NM; van Wijngaarden, JP, 2015) |
| "Hyperhomocysteinemia is an independent cardiovascular risk factor that has been associated with atherosclerotic vascular diseases and ischemic heart attacks." | ( Kan, MY; Lai, WK, 2015) |
| "Hyperhomocysteinemia is likely related to the enhanced production of pro-inflammatory cytokines including IL-1β." | ( Battastini, AM; Bergamin, LS; Coutinho-Silva, R; de Souza Wyse, AT; Morrone, FB; Zanin, RF, 2015) |
| "Hyperhomocysteinemia is frequently present in patients with cirrhosis and is associated with severe liver disease and reduced graft and patient survival after liver transplantation." | ( Bain, VG; Bhanji, RA; Ma, M; Montano-Loza, AJ, 2016) |
| "Severe hyperhomocysteinemia is caused by increased plasma levels of homocysteine (Hcy), a methionine derivative, and is associated with cerebral disorders." | ( Kolling, J; Longoni, A; Loureiro, S; Petenuzzo, L; Scherer, EB; Siebert, C; Weis, S; Wyse, AT, 2016) |
| "Hyperhomocysteinemia is characterized by an abnormally high level of homocysteine (Hcy) in the blood and is associated with cardiovascular diseases such as atherosclerosis." | ( Hua, P; Li, T; Liu, B; Liu, N; Shi, Y; Tian, X; Yan, Y, 2016) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases." | ( Chen, D; Fang, K; Gao, P; Hu, Y; Li, J; Liu, K; Qin, X; Song, J; Sun, K; Tang, X; Wang, L; Wang, X; Wu, T; Wu, Y, 2017) |
| "Hyperhomocysteinemia is associated with insulin resistance and predicts cardiovascular diseases." | ( Feng, X; Xu, Y, 2017) |
| "Hyperhomocysteinemia is a risk factor for many human diseases, including pulmonary pathologies." | ( Belskikh, ES; Bulatetskiy, SV; Medvedev, DV; Ryabkov, AN; Uryasev, OM; Zvyagina, VI, 2017) |
| "In general, hyperhomocysteinemia is increasingly appreciated as a risk factor for various diseases, including osteoporosis." | ( Djonic, D; Djuric, D; Djuric, M; Hrncic, D; Milovanovic, P; Mutavdzic, D; Radotic, K; Rasic-Markovic, A; Stankovic, M; Stanojlovic, O, 2017) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular disease and is associated with primary causes of mortality and morbidity throughout the world." | ( Azad, MAK; Huang, P; Liu, G; Ren, W; Teklebrh, T; Yan, W; Yin, Y; Zhou, X, 2018) |
| "Preoperative hyperhomocysteinemia is associated with the development of postoperative cognitive decline." | ( Absalom, AR; de Bock, GH; Gernaat, SAM; Huisman, MG; Izaks, GJ; van der Wal-Huisman, H; van Leeuwen, BL; Weerink, LBM, 2018) |
| "Mild hyperhomocysteinemia is considered a risk factor for development of neurodegenerative diseases." | ( de S Moreira, D; Figueiró, PW; Guma, FCR; Manfredini, V; Prezzi, CA; Rohden, F; Siebert, C; Wyse, ATS, 2018) |
| "Hyperhomocysteinemia is a risk factor for endothelial dysfunction and is associated with primary open-angle glaucoma as well as secondary open-angle glaucoma in the pseudoexfoliation syndrome." | ( Hohberger, B; Jünemann, A; Rejdak, R, 2018) |
| "Hyperhomocysteinemia is a state in which too much homocysteine is present in the body." | ( Kim, H; Kim, J; Kwon, Y; Roh, H, 2018) |
| "Hyperhomocysteinemia is linked with genetic factors and family nutritional scheme, increasing the risk for atherosclerosis." | ( Colak, E; Dimitrijevic-Sreckovic, V; Gacic, J; Janeski, H; Janeski, N; Mrdovic, I; Soldatovic, I; Srećković, B; Sumarac-Dumanovic, M, 2018) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis, which may also be associated with retinal vascular disease, diabetic retinopathy, retinal vein occlusion, and glaucoma." | ( Ke, CY; Lee, YJ; Lin, PK; Tien, N, 2018) |
| "Hyperhomocysteinemia is an independent risk factor for dementia, including Alzheimer's disease." | ( Du, YJ; Fang, YY; Lin, L; Lu, Y; Shi, Y; Tang, N; Tian, Q; Wang, JZ; Wang, Q; Wang, XM; Zeng, P; Zhou, XW, 2019) |
| "Hyperhomocysteinemia is a pathological consequence of alcoholic liver disease (ALD) and is attributed to hepatic endoplasmic reticulum (ER) stress and insulin resistance." | ( Ohashi, K; Tsuchiya, H, 2016) |
| "Hyperhomocysteinemia is found to be closely associated with an enhanced risk of cerebral venous thrombosis." | ( D'Cruz, S; Kapur, V; Kaur, R, 2019) |
| "Hyperhomocysteinemia is associated with increased cardiovascular disease risk." | ( Dobiszewski, S; Loor, JJ; Luchtel, RA; Miller, JW; Nass, CA; Neuman, JC; Pritchard, SK; Saande, CJ; Schalinske, KL; Snavely, SE; Vailati-Riboni, M; Worrall, DM, 2019) |
| "Hyperhomocysteinemia is a metabolic disorder caused by various enzyme defects in methionine metabolism." | ( Büyükbabani, N; Çaytemel, C; Topaloğlu Demir, F; Türkoğlu, Z; Uzuner, EG, 2019) |
| "Hyperhomocysteinemia is a known determinant of platelet function abnormalities." | ( De Luca, G; Marcolongo, M; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Tonon, F; Verdoia, M, 2020) |
| "Hyperhomocysteinemia is a well-known cause of cognitive impairment and neurodegeneration." | ( Aburashed, ZO; Alzoubi, KH; Mayyas, F, 2020) |
| "Hyperhomocysteinemia is a common metabolic disorder that imposes major adverse health consequences." | ( Finnell, RH; Hou, J; Huang, L; Jin, L; Lin, Y; Liu, Z; Ma, J; Mei, X; Nie, J; Qi, D; Saiyin, H; Si, W; Wang, H; Wang, J; Xu, W; Xue, Y; Ye, J; Zhang, T; Zhao, J; Zhao, S; Zhao, Y; Zhu, P, 2020) |
| "Hyperhomocysteinemia is associated with poor health, including cardiovascular and brain diseases." | ( Chen, M; Wu, B; Xu, H; Zhang, T; Zhou, C, 2020) |
| "Maternal hyperhomocysteinemia is one of the common complications of pregnancy that causes offspring cognitive deficits during postnatal development." | ( Arutjunyan, AV; Kerkeshko, GO; Milyutina, YP; Shcherbitskaia, AD; Tumanova, NL; Vasilev, DS; Zalozniaia, IV, 2020) |
| "Hyperhomocysteinemia is associated with coronary artery disease (CAD)." | ( Bruzzese, L; Chefrour, M; Criado, C; Cuisset, T; Deharo, P; Fenouillet, E; Fromonot, J; Gastaldi, M; Gaubert, M; Gaudry, M; Guieu, R; Guiol, C; Kipson, N; Mace, P; Marlinge, M; Mottola, G; Paganelli, F; Ruf, J; Vairo, D, 2020) |
| "Hyperhomocysteinemia is recognized as risk factor for cardiovascular and age-associated diseases." | ( Accinni, R; Caimi, TM; Dellanoce, C; Montorsi, M; Mrakic-Sposta, S; Vezzoli, A; Vietti, D, 2020) |
| "Hyperhomocysteinemia is a known risk factor for coronary artery disease." | ( Cornett, EM; Fuller, MC; Jeha, GM; Kaye, AD; Kevil, CG; Lerner, ZI; Pham, AD; Sibley, GT; Urits, I; Viswanath, O, 2020) |
| "Hyperhomocysteinemia is an independent risk factor for various cardiovascular diseases, including atherosclerosis, and damage to vascular function plays an initial role in its pathogenesis." | ( Gui, HL; Jiang, Q; Li, B; Si, X; Tan, DH; Tian, JL; Wang, L; Zhang, Y, 2021) |
| "Maternal hyperhomocysteinemia is one of the common complications of pregnancy that causes offspring cognitive deficits during postnatal development." | ( Arutjunyan, AV; Mikhel, AV; Milyutina, YP; Shcherbitskaia, AD; Tumanova, NL; Vasilev, DS; Zalozniaia, IV, 2021) |
| "Mild hyperhomocysteinemia is a risk factor for psychiatric and neurodegenerative diseases, whose mechanisms between them are not well-known." | ( Bobermin, LD; Dos Santos, TM; Quincozes-Santos, A; Siebert, C; Wyse, ATS, 2022) |
| "Hyperhomocysteinemia is a risk factor for many diseases, including reproductive disorders in men." | ( Belskikh, ES; Zvyagina, VI, 2021) |
| "Hyperhomocysteinemia is commonly found in CKD patients because of impaired renal metabolism and reduced renal excretion." | ( Aiello, V; Angelini, A; Capelli, I; Cappuccilli, ML; Cianciolo, G; Croci Chiocchini, AL; Iacovella, F; Magnoni, G; Mancini, R; Napoletano, A; Troiano, A, 2021) |
| "Hyperhomocysteinemia is an independent risk factor for cardiovascular diseases." | ( Dong, Y; He, Q; Hocher, B; Hocher, CF; Hong, X; Kraemer, BK; Li, J; Lv, Y; Xie, M; Yang, Y; Ye, X; Yuan, S; Zeng, Y, 2021) |
| "The prevalence of hyperhomocysteinemia is 35." | ( Dong, Y; He, Q; Hocher, B; Hocher, CF; Hong, X; Kraemer, BK; Li, J; Lv, Y; Xie, M; Yang, Y; Ye, X; Yuan, S; Zeng, Y, 2021) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerosis." | ( Cai, BQ; Huang, DD; Ren, YG; Yang, YP, 2022) |
| "Hyperhomocysteinemia is frequently observed in CKD and End-Stage Kidney Disease (ESKD), but its representation as a prognostic marker for CKD outcomes is still not fully clear." | ( Wang, AY; Wu, HHL, 2022) |
| "Hyperhomocysteinemia is an independent risk factor for atherosclerosis, even in early childhood." | ( Gil, APR; Katsa, ME, 2022) |
| "Hyperhomocysteinemia is associated with premature atherosclerosis and vascular events and it is an important risk factor for cerebrovascular accidents." | ( Mr, R; Paul, K, 2022) |
| "hyperhomocysteinemiais significantly correlated with an increased risk of CAD, but MTHFR C677T gene polymorphism might not contribute to increased CAD risk." | ( Romdoni, R; Sargowo, D; Sugijo, H; Widjajanto, E, 2022) |
| "Hyperhomocysteinemia is associated with blood-brain-barrier (BBB) disruption in brain disorders." | ( Li, C; Zhang, B, 2022) |
| "Hyperhomocysteinemia is a risk factor for not only AD and VaD but also FTD." | ( Jia, J; Li, T; Quan, M; Song, Y, 2022) |
| "Hyperhomocysteinemia is implicated in the pathogenesis of neurodegenerative disorders, including PD." | ( Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE; Elewa, YHA; Papadakis, M; Zahran, MH, 2023) |
| "In summary, hyperhomocysteinemia is an important potential cause of ischaemic stroke and may result from genetic, dietary, and social factors." | ( Chandratheva, A; Chen, J; Coughlan, CH; Goodison, W; Murphy, E; Rees, A, 2023) |
| "Hyperhomocysteinemia is a rare neurometabolic syndrome with diverse manifestations in the pediatric age group, thereby posing a diagnostic challenge." | ( Arunachal, G; Bhasin, H; Chandran, M; Danda, S; Garg, D; Korula, S; Malik, P; Oommen, SP; Saini, AG; Sharma, S; Thomas, M; Yoganathan, S, 2023) |
| "Hyperhomocysteinemia is one of cardiovascular disease risk factors and fasting homocysteine levels are significantly elevated in male compared to female acute coronary syndrome (ACS) patients with normal renal function." | ( Chen, H; Kuang, J; Ning, X; Shang, K; Xue, A; Yan, X, 2023) |
| "Hyperhomocysteinemia is a well-known marker that is associated with an increased risk of atherosclerosis due to its toxic effect on endothelial cells." | ( Al-Khlaiwi, T; Almushawah, A; Alsomali, A; Habib, SA; Habib, SS, 2023) |
| "Hyperhomocysteinemia is a recognized risk factor for atherosclerotic and cardiovascular diseases." | ( Gu, J; Lei, C; Zhang, M, 2023) |
| Excerpt | Reference |
|---|
| "Hyperhomocysteinemia has been identified as a potential risk factor for atherosclerosis." | ( Beilby, JP; Hung, J; McQuillan, BM; Nidorf, M; Thompson, PL, 1999) |
| "Hyperhomocysteinemia has recently been recognized as a risk factor for venous thromboembolic disease." | ( Cable, GG, 1999) |
| "Moreover, mild hyperhomocysteinemia has been shown to be associated with a 2 to 4-fold increased relative risk for coronary artery disease, cerebrovascular disease, and peripheral arterial occlusive disease." | ( Solenthaler, M; Wuillemin, WA, 1999) |
| "Hyperhomocysteinemia has been recognised as an independent risk factor for cardiovascular, cerebrovascular and peripheral artery disease." | ( Fiedor, P; Polakowska, MJ; Socha, MW; Socha-Urbanek, K, 1999) |
| "Hyperhomocysteinemia has been found to be an important risk factor for cardiovascular disease in large studies." | ( Beloqui, O; Cienfuegos, JA; Herrero, JI; Pardo, F; Prieto, J; Quiroga, J; Sangro, B, 2000) |
| "Hyperhomocysteinemia has recently emerged as a potentially major risk factor in the pathogenesis of coronary artery disease." | ( Robinson, K; Seshadri, N, 1999) |
| "Hyperhomocysteinemia has been associated with premature atherothrombotic vascular disease." | ( Stehouwer, CD; van Guldener, C, 2000) |
| "Hyperhomocysteinemia has been increasingly recognized as an important risk factor for elevated atherosclerotic vascular disease in chronic renal failure." | ( Graefe, U; Henning, BF; Tepel, M; Zidek, W, 2000) |
| "Hyperhomocysteinemia has emerged as an important risk factor for cardiovascular disease." | ( De Souza , C; Fonseca, V; Keebler, ME, 2001) |
| "In recent years hyperhomocysteinemia has been established as a new risk factor for arterial and venous thrombosis." | ( Dilaveraki, E; Emmanouel, D; Ganotakis, E; Gravanis, A; Kouroumalis, EA; Koutroubakis, IE; Mouzas, IA; Vardas, E; Vlachonikolis, IG; Vrentzos, G, 2000) |
| "Mild hyperhomocysteinemia has been suggested as a new, independent risk factor for cardiovascular disease." | ( Amores-Sánchez, MI; Medina, M; Urdiales, JL, 2001) |
| "Hyperhomocysteinemia has been recognized as an independent risk factor for atherosclerotic disease." | ( Gromeier, S; Herrmann, W; Julius, U; Pietzsch, J; Schorr, H, 2001) |
| "Hyperhomocysteinemia has also been observed in infections and inflammatory diseases." | ( Artner-Dworzak, E; Fuchs, D; Jaeger, M; Leblhuber, F; Widner, B; Wirleitner, B, 2001) |
| "Hyperhomocysteinemia has never been considered as a possible risk factor in renal artery stenosis." | ( Corrocher, R; Faccini, G; Friso, S; Girelli, D; Olivieri, O; Pignatti, PF; Pizzolo, F; Stranieri, C; Trabetti, E, 2001) |
| "Hyperhomocysteinemia has been linked with atherosclerosis, including that in the cerebral vasculature." | ( Cohen, B; Lima, J; Oppenheimer, SM; Sen, S, 2002) |
| "Hyperhomocysteinemia has been shown to adversely affect vascular function." | ( Ai, VH; Chow, WS; Lam, KS; O, K; Siow, YL; Tan, KC, 2002) |
| "Hyperhomocysteinemia has been established as an important risk factor for cardiovascular diseases." | ( Deutschmann, H; Haas, A; Leitner, FJ; Renner, W; Schmut, O; Semmelrock, J; Stanger, O; Weger, M, 2002) |
| "Hyperhomocysteinemia has been associated with an increased risk of CVD, although prospective randomized trials designed to prove causality are still ongoing." | ( Bostom, AG; Friedman, AN; Levey, AS; Rosenberg, IH; Selhub, J, 2002) |
| "Hyperhomocysteinemia has been proposed to inhibit the protein C anticoagulant system through 2 mechanisms: decreased generation of activated protein C (APC) by thrombin, and resistance to APC caused by decreased inactivation of factor Va (FVa)." | ( Arning, E; Bottiglieri, T; Erger, RA; Fernández, JA; Griffin, JH; Haynes, WG; Heistad, DD; Lentz, SR; Malinow, MR; Piegors, DJ, 2002) |
| "Hyperhomocysteinemia has been recognized as an important risk factor for atherosclerotic vascular disease." | ( Caldera, A; Dec, GW, 2002) |
| "Hyperhomocysteinemia has been commonly found among heart transplant recipients (average prevalence 51% to 76%)." | ( Caldera, A; Dec, GW, 2002) |
| "Hyperhomocysteinemia has been associated with several pregnancy complications." | ( Abdelmouttaleb, I; Barbarino, P; Barbé, F; Boutroy, JL; Chéry, C; Gérard, P; Guéant, JL; Lequere, C, 2002) |
| "Hyperhomocysteinemia has been shown to be an independent risk factor for cognitive dysfunction." | ( Miller, AL, 2003) |
| "Hyperhomocysteinemia has been reported in Asian Indians (people from Indian subcontinent) to be related to relatively low plasma levels of folate and vitamin B-12." | ( Abate, N; Cabo-Chan, AV; Chandalia, M; Devaraj, S; Grundy, SM; Jialal, I, 2003) |
| "Pregnant women with hyperhomocysteinemia have a 7." | ( Lailla, JM; López-Quesada, E; Vilaseca, MA, 2003) |
| "Alcohol-induced hyperhomocysteinemia has been reported in rats and humans." | ( Ji, C; Kaplowitz, N, 2003) |
| "Hyperhomocysteinemia has long been recognized as a risk factor for cardiovascular disease." | ( Handy, DE; Loscalzo, J, 2003) |
| "Hyperhomocysteinemia has probably a causal role in this original case of acral purpura." | ( Boeckler, P; Grange, F; Grosshans, E; Guillaume, JC; Krzisch, S, 2003) |
| "Moderate hyperhomocysteinemia has been identified as a new independent risk factor for cardiovascular and neurodegenerative diseases." | ( Bodis, M; Geisel, J; Herrmann, W; Hübner, U; Knapp, JP; Obeid, R; Schorr, H, 2003) |
| "Hyperhomocysteinemia has been associated with increased risk of atherosclerosis and myocardial infarction by a number of prospective case-control studies." | ( Gauthier, GM; Keevil, JG; McBride, PE, 2003) |
| "Hyperhomocysteinemia has been linked with various atherosclerotic diseases, but has not been evaluated sufficiently as a risk factor for the development of chronic kidney disease (CKD) in the general population." | ( Hata, J; Hirakata, H; Iida, M; Kato, I; Kiyohara, Y; Kubo, M; Nakamura, H; Ninomiya, T; Oishi, Y; Okubo, K; Tanaka, K; Tanizaki, Y, 2004) |
| "Hyperhomocysteinemia has been implicated in the high vascular event rate in patients with chronic renal failure." | ( van Guldener, C, 2005) |
| "Hyperhomocysteinemia has emerged as a novel risk factor for myocardial infarction (MI)." | ( D'Almeida, V; Dabela, ML; Fonseca, FA; Helfenstein, T; Izar, MC; Matheus, SC; Relvas, WG; Rodrigues, PR; Santos, AO; Sousa, EF; Souza, FG; Taglieri, R; Tufik, S, 2005) |
| "Hyperhomocysteinemia has been identified as a risk factor for cerebrovascular disease, dementia, impaired cognitive function and depression." | ( Biagio Mercuri, N; De Sarro, G; Ferreri Ibbadu, G; Gallelli, L; Mancuso, F; Siniscalchi, A, 2005) |
| "Hyperhomocysteinemia has been identified as an independent risk factor for coronary artery disease." | ( Adachi, T; Horiuchi, M; Kobayashi, K; Nagai, Y; Nakashima, Y; Nihei, S; Suzuka, H; Tasaki, H; Yamashita, K, 2005) |
| "Hyperhomocysteinemia has been proposed as an important risk factor for ischemic stroke worldwide, but data available from the Indian subcontinent is scarce." | ( Das, CP; Khullar, M; Lal, V; Majumdar, S; Modi, M; Prabhakar, S, 2005) |
| "Hyperhomocysteinemia has been recently described in patients with inflammatory bowel disease (IBD), that could be related to the increased risk for thrombosis that exists in this disease." | ( Casis Herce, B; Fernández-Miranda, C; Gómez de la Cámara, A; Gómez González, P; Martínez López, J; Martínez Prieto, M; Sáenz-López Pérez, S; Sánchez Gómez, F, 2005) |
| "Hyperhomocysteinemia has emerged as a major, independent risk factor for cardiovascular diseases." | ( Aksoy, Y; Kosar, F; Ozerol, I; Sincer, I, 2006) |
| "Hyperhomocysteinemia has also been recognized as a risk factor for cardiovascular disease, yet there are limited data on the prevalence of hyperhomocysteinemia in patients with acromegaly." | ( Hekimsoy, Z; Ozmen, B; Ulusoy, S, 2005) |
| "Hyperhomocysteinemia has been associated with other vascular effects such as atherothrombosis and endothelial dysfunction due to its auto-oxidative potential, thereby increasing the production of reactive oxygen species." | ( Cook, S; Hess, OM, 2005) |
| "Hyperhomocysteinemia has been reported to be associated with both vascular structure alteration and increased cardiovascular risk." | ( Munakata, M; Tayama, J; Toyota, T; Yoshinaga, K, 2006) |
| "Hyperhomocysteinemia has been identified as a risk factor for venous and arterial thrombosis especially in adult populations." | ( Areekul, S; Atamasirikul, K; Cheeramakara, C; Chotsuppakarn, S; Chuansumrit, A; Sirachainan, N; Tapanapruksakul, P; Visudtibhan, A, 2006) |
| "Hyperhomocysteinemia has been identified as a risk factor for neurological disorders." | ( Alberto, JM; Blaise, SA; Bossenmeyer-Pourié, C; Daval, JL; Guéant, JL; Nédélec, E; Schroeder, H, 2007) |
| "Hyperhomocysteinemia has been suggested to induce hypertension due to its role in endothelial dysfunction." | ( Fu, M; Haugen, E; Kondziella, D; Zetterberg, H, 2008) |
| "Hyperhomocysteinemia has been repeatedly reported in PD patients; the increase, however, seems mostly related to the methylated catabolism of l-Dopa, the main pharmacological treatment of PD." | ( Blandini, F; Martignoni, E; Nappi, G; Pacchetti, C; Tassorelli, C; Zangaglia, R, 2007) |
| "Hyperhomocysteinemia has been associated with vascular disease in many epidemiologic studies, but only a few have reported on the relation between hyperhomocysteinemia and aneurysms of the abdominal aorta (AAAs)." | ( Blom, HJ; den Heijer, M; Graafsma, SJ; Hermus, AR; Kranendonk, SE; Peeters, AC; van Landeghem, BA, 2007) |
| "Hyperhomocysteinemia has become established as one of the commonest conditions associated with venous and arterial thrombosis." | ( Burcombe, RJ; Cladd, H; Cooper, P; Gatt, A; Makris, A; Makris, M; Smith, JM; Thompson, D, 2007) |
| "Hyperhomocysteinemia has been identified as a potential risk for atherosclerotic disease in epidemiologic studies." | ( Hillenbrand, A; Hillenbrand, R; Liewald, F; Zimmermann, J, 2008) |
| "Hyperhomocysteinemia has occasionally been reported in patients with phenylketonuria (PKU) and B-vitamin deficiency." | ( Bodamer, OA; Födinger, M; Herle, M; Huemer, M; Möslinger, D; Mühl, A; Stöckler-Ipsiroglu, S; Ulmer, H; Weigmann, C, 2008) |
| "In the last decade hyperhomocysteinemia has become an element of great interest as a recognized factor of independent risk for atherotrombosis." | ( Bambara, LM; Biasi, D; Caramaschi, P; Patuzzo, G; Tinazzi, I, 2007) |
| "Hyperhomocysteinemia has often been associated with coronary artery disease, vascular thrombosis and the development of premature atherosclerosis." | ( Belin, N; Delabar, JM; Ducros, V; Hamelet, J; Janel, N; Noll, C; Paul, JL, 2009) |
| "Hyperhomocysteinemia has long been associated with atherosclerosis and thrombosis and is an independent risk factor for cardiovascular disease." | ( Dayal, S; DiBello, PM; Jacobsen, DW; Kaveti, S; Kinter, M; Lentz, SR; Zhang, D, 2010) |
| "Hyperhomocysteinemia has been found to be negatively associated with the vitamin B group, especially folate and cobalamin." | ( Altantsetseg, P; Erdenekhuu, N; Huang, SL; Mungun-Ulzii, K; Zulgerel, D, 2010) |
| "Hyperhomocysteinemia has been implicated in dementia and neurodegenerative disease." | ( Fujiki, Y; Hirashima, Y; Kanouchi, H; Matsumoto, M; Nishiyama, K; Oka, T; Okabe, M; Seshimo, S, 2010) |
| "Genetic and dietary hyperhomocysteinemia has been found to decrease high density lipoproteins (HDL) and their apolipoprotein A1 (APOA1)." | ( Arnal, C; Barranquero, C; Bregante, MA; García-Gimeno, MA; Gascón, S; Godino, J; Guillén, N; Guzmán, MA; Hernandez, E; Lou-Bonafonte, JM; Navarro, MA; Nuño-Ayala, M; Osada, J; Royo-Cañas, M; Sarría, AJ, 2010) |
| "Mild to moderate hyperhomocysteinemia has been identified as a strong predictor of cardiovascular disease, independent from classical atherothrombotic risk factors." | ( Blom, HJ; Smulders, YM, 2011) |
| "Hyperhomocysteinemia has been associated with cognitive dysfunction and dementia." | ( Iliceto, G; Lamberti, P; Lamberti, SV; Logroscino, G; Santamato, A; Zoccolella, S, 2010) |
| "Abstract Hyperhomocysteinemia has recently been identified as an important risk factor for Alzheimer's disease (AD)." | ( Ahmadian, S; Aryapour, H; Hoveizi, E; Karima, O; Khodadadi, S; Riazi, GH, 2012) |
| "Hyperhomocysteinemia has been shown to increase the incidence of osteoporosis and osteoporotic fractures." | ( Cho, CS; Kim, KJ; Kim, WU; Oh, IH; Park, SJ, 2012) |
| "Hyperhomocysteinemia has been implicated in vascular disease for over a decade now, and can be treated with B vitamins." | ( Ali, A; Bhargava, S; Parakh, R; Saxena, R; Srivastava, LM, 2012) |
| "Hyperhomocysteinemia has been implicated in endothelial dysfunction and cardiovascular disease." | ( Garg, MK; Kulkarni, MV; Mahalle, N; Naik, SS, 2013) |
| "Hyperhomocysteinemia has been linked to cardiovascular diseases, and defects in methyl group metabolism, often resulting in hyperhomocysteinemia, are among the key molecular events postulated to play a role in liver injury." | ( Chrudinová, M; Demianová, Z; Jiráček, J; Kořínek, M; Mládková, J; Selicharová, I, 2013) |
| "Patients with hyperhomocysteinemia have increased risk for cardiovascular events that potentially involve enhanced inflammation." | ( Aukrust, P; Holven, KB; Nenseter, MS; Ose, L, 2014) |
| "Hyperhomocysteinemia has been associated with enhanced platelet function, impaired endothelial function and prothrombotic status, thus increasing the risk of cardiovascular events." | ( Barbieri, L; Cassetti, E; De Luca, G; Di Giovine, G; Marino, P; Schaffer, A; Verdoia, M, 2015) |
| "Hyperhomocysteinemia has been considered a risk factor for neuropsychiatric disorders, but the mechanisms involved in this process have not been completely elucidated." | ( D'Almeida, V; de Rezende, MM, 2014) |
| "The negative impact hyperhomocysteinemia has on graft and patient survival is not related to thrombosis." | ( Bain, VG; Bhanji, RA; Ma, M; Montano-Loza, AJ, 2016) |
| "Hyperhomocysteinemia has been identified as a risk factor for CAD due to increased thrombogenicity, oxidative stress status and endothelial dysfunction." | ( Barbieri, L; Cassetti, E; De Luca, G; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "Hyperhomocysteinemia has been reported in Greyhounds with suspected chronic enteropathy." | ( Bridges, CS; Couto, CG; Grützner, N; Heilmann, RM; Iazbik, MC; Lopes, R; Steiner, JM; Suchodolski, JS, 2017) |
| "Hyperhomocysteinemia has also been associated with total and CVD mortality." | ( Katsiki, N; Mikhailidis, DP; Perez-Martinez, P, 2017) |
| "Hyperhomocysteinemia has been suspected of favoring thrombosis." | ( Adnaoui, M; Ammouri, W; Harmouche, H; Maamar, M; Tazi, ZM, 2017) |
| "Hyperhomocysteinemia has been associated with different pathologies, including cardiovascular diseases, hypertension, diabetes, and breast cancer (BC)." | ( Delgado-Saucedo, JI; Figuera, LE; Gallegos-Arreola, MP; Morán-Mendoza, A; Puebla-Pérez, AM; Rodríguez-Arévalo, F; Varela Almanza, KM; Zúñiga-González, GM, 2018) |
| "Hyperhomocysteinemia has been considered as a risk factor for systemic atherosclerosis, cardiovascular disease (CVD) and stroke and many epidemiologic and case-controlled studies have demonstrated its association with these complications." | ( Chrysant, GS; Chrysant, SG, 2018) |
| "Hyperhomocysteinemia has been postulated as a potential risk factor for the development and progression of diabetic retinopathy." | ( Gupta, P; John, D; John, SS; Rebekah, G, 2018) |
| "Hyperhomocysteinemia has been implicated in several neurodegenerative disorders including ischemic stroke." | ( Allan, AM; Brigman, J; Jacobsen, DW; Jindal, A; Miller, JW; Paul, S; Poddar, R; Rajagopal, S; Winter, L, 2019) |
| "Hyperhomocysteinemia has an independent effect on LVH." | ( Chen, Y; Guo, X; Sun, Y; Yang, H; Yu, S; Zheng, L, 2020) |
| "Hyperhomocysteinemia has undoubtedly a central role in such a prominent cardiovascular burden." | ( Bergamini, C; Capelli, I; Cappuccilli, M; Cianciolo, G; Conte, D; Donati, G; Giacomelli, FA; La Manna, G; Natali, T, 2020) |
| "People with hyperhomocysteinemia have a higher incidence of CKD, Hyperhomocysteinemia may also be an independent risk factor for CKD in the general population." | ( Chen, W; Feng, J; Ji, P; Liu, Y; Wan, H; Zhang, J, 2023) |